<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29176824</article-id><article-id pub-id-type="pmc">5720814</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0006068</article-id><article-id pub-id-type="publisher-id">PNTD-D-17-01159</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Snakebite</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>South America</subject><subj-group><subject>Brazil</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Ethnicities</subject><subj-group><subject>European People</subject><subj-group><subject>Slavic People</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Venoms</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Venoms</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Adverse Events</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Glycobiology</subject><subj-group><subject>Glycoproteins</subject><subj-group><subject>Fibrinogen</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Adverse Reactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Creatine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Creatine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Safety and efficacy of a freeze-dried trivalent antivenom for snakebites in the Brazilian Amazon: An open randomized controlled phase IIb clinical trial</article-title><alt-title alt-title-type="running-head">Efficacy and safety of freeze-dried trivalent antivenom</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mendon&#x000e7;a-da-Silva</surname><given-names>Iran</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Magela Tavares</surname><given-names>Ant&#x000f4;nio</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sachett</surname><given-names>Jacqueline</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sardinha</surname><given-names>Jos&#x000e9; Felipe</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zaparolli</surname><given-names>Lilian</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gomes Santos</surname><given-names>Maria F&#x000e1;tima</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lacerda</surname><given-names>Marcus</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0848-1940</contrib-id><name><surname>Monteiro</surname><given-names>Wuelton Marcelo</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Escola Superior de Sa&#x000fa;de, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Departamento de Ensino e Pesquisa, Funda&#x000e7;&#x000e3;o de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Instituto de Biologia do Ex&#x000e9;rcito, Rio de Janeiro, Rio de Janeiro, Brazil</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Laborat&#x000f3;rio Qu&#x000ed;mico e Farmac&#x000ea;utico do Ex&#x000e9;rcito, Rio de Janeiro, Rio de Janeiro, Brazil</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Instituto Le&#x000f4;nidas &#x00026; Maria Deane, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Manaus, Amazonas, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Calvete</surname><given-names>Juan J</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Instituto de Biomedicina de Valencia, SPAIN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>wueltonmm@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2017</year></pub-date><volume>11</volume><issue>11</issue><elocation-id>e0006068</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Mendon&#x000e7;a-da-Silva et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Mendon&#x000e7;a-da-Silva et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pntd.0006068.pdf"/><abstract><sec id="sec001"><title>Background</title><p>In tropical areas, a major concern regarding snakebites treatment effectiveness relates to the failure in liquid antivenom (AV) distribution due to the lack of an adequate cold chain in remote areas. To minimize this problem, freeze-drying has been suggested to improve AV stability.</p></sec><sec id="sec002"><title>Methods and findings</title><p>This study compares the safety and efficacy of a freeze-dried trivalent antivenom (FDTAV) and the standard liquid AV provided by the Brazilian Ministry of Health (SLAV) to treat <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> snakebites. This was a prospective, randomized, open, phase IIb trial, carried out from June 2005 to May 2008 in the Brazilian Amazon. Primary efficacy endpoints were the suppression of clinical manifestations and return of hemostasis and renal function markers to normal ranges within the first 24 hours of follow-up. Primary safety endpoint was the presence of early adverse reactions (EAR) in the first 24 hours after treatment. FDTAV thermal stability was determined by estimating AV potency over one year at 56&#x000b0;C. Of the patients recruited, 65 and 51 were assigned to FDTAV and SLAV groups, respectively. Only mild EARs were reported, and they were not different between groups. There were no differences in fibrinogen (p = 0.911) and clotting time (p = 0.982) recovery between FDTAV and SLAV treated groups for <italic>Bothrops</italic> snakebites. For <italic>Lachesis</italic> and <italic>Crotalus</italic> snakebites, coagulation parameters and creatine phosphokinase presented normal values 24 hours after AV therapy for both antivenoms.</p></sec><sec id="sec003"><title>Conclusions/Significance</title><p>Since promising results were observed for efficacy, safety and thermal stability, our results indicate that FDTAV is suitable for a larger phase III trial.</p></sec><sec id="sec004"><title>Trial registration</title><p>ISRCTNregistry: ISRCTN12845255; DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/ISRCTN12845255">10.1186/ISRCTN12845255</ext-link> (<ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN12845255">http://www.isrctn.com/ISRCTN12845255</ext-link>).</p></sec></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Antivenoms (AV) are included in the WHO List of Essential Medicines, being the only treatment available for snakebites envenomings. In Brazil, five types of liquid snake AVs are distributed by the Ministry of Health for national use free of charge to patients. In remote areas, lack of an adequate cold chain impairs AV distribution to health facilities resulting in delay in patient care and, ultimately, in higher complication and case fatality rate. To minimize this problem, a freeze-drying process has been suggested to improve the stability of AVs, but freeze-dried AVs efficacy and safety evidence obtained from clinical trials is still very limited. Freeze-drying is a process by which water is removed from a sample without the need to apply heat. Benefits of lyophilization are: a) Samples are processed in aseptic conditions; b) Process does not use heat, ensuring formulation stability; c) Increases shelf life; d) Samples can be stored at room temperature for a long time; and e) Reduces weight and volume of samples, which is ideal for distribution. In this study, a freeze-dryed formulation is presented as a good alternative for a more stable trivalent antivenom in regions of the Amazon where high temperatures are common and the cold chain is poor. Our results suggest that such a product is adequate for a phase III trial.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Instituto de Biologia do Ex&#x000e9;rcito</institution></funding-source><award-id>Agreement term 0404400/2004</award-id><principal-award-recipient><name><surname>Mendon&#x000e7;a-da-Silva</surname><given-names>Iran</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Funda&#x000e7;&#x000e3;o de Medicina Tropical Doutor Heitor Vieira Dourado</institution></funding-source><award-id>Agreement term 0404401/2005</award-id><principal-award-recipient><name><surname>Mendon&#x000e7;a-da-Silva</surname><given-names>Iran</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by IBEx (Army Institute of Biology - Rio de Janeiro, Brazil) and Tropical Medicine Foundation Dr. Heitor Vieira Dourado (Manaus, Brazil) (Agreement terms 0404400/2004 and 0404401/2005). Freeze-dried trivalent antivenom (FDTA) was produced by the partnership between Butantan Institute (S&#x000e3;o Paulo, Brazil) and IBEx (Rio de Janeiro, Brazil). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="5"/><page-count count="21"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2017-12-07</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Snakebites are a serious public health problem in tropical countries, with higher morbidity and case fatality rates in poor, underdeveloped, rural and remote rainforest areas. At least 421,000 envenomings and 20,000 deaths occur each year due to snakebites globally, but these figures may be as high as 1,841,000 envenomings and 94,000 deaths [<xref rid="pntd.0006068.ref001" ref-type="bibr">1</xref>]. Additionally, 400,000 amputations and other severe health consequences such as infection, tetanus, scarring, contractures, and psychological sequelae have been recorded [<xref rid="pntd.0006068.ref002" ref-type="bibr">2</xref>]. In Brazil, from 2000 to 2015 a total of 416,109 snakebites were recorded by the Brazilian official surveillance system, with 26,000 cases on average per year. Snakebites incidence is higher in the Brazilian Amazon states, with a rate of 55.4 cases/100,000 inhabitants in 2015, and considered an occupational health problem of rural and riverine populations [<xref rid="pntd.0006068.ref003" ref-type="bibr">3</xref>]. However, the true burden of snakebites is probably higher and difficult to estimate since only a few countries have a reliable system for epidemiological surveillance of these events [<xref rid="pntd.0006068.ref004" ref-type="bibr">4</xref>]. In the Brazilian Amazon, the case fatality rate has been estimated to be 0.6% and associated with older age and delayed medical assistance [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>].</p><p>The <italic>Bothrops</italic> genus is responsible for 80&#x02013;90% of snakebites in the Brazilian Amazon [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0006068.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0006068.ref007" ref-type="bibr">7</xref>]. In this region, <italic>Bothrops</italic> envenoming results in pain, swelling, regional lymphadenopathy, ecchymosis, blistering, and necrosis as the most common local manifestations [<xref rid="pntd.0006068.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0006068.ref008" ref-type="bibr">8</xref>,<xref rid="pntd.0006068.ref009" ref-type="bibr">9</xref>]. Systemic bleeding and acute renal failure are common systemic complications after <italic>Bothrops</italic> envenomings [<xref rid="pntd.0006068.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0006068.ref009" ref-type="bibr">9</xref>]. Clinical manifestations at the <italic>Bothrops</italic> and <italic>Lachesis</italic> bite sites are similar, with an intense tissue damage evidenced by pain, edema, blisters, bleeding, and ecchymosis [<xref rid="pntd.0006068.ref010" ref-type="bibr">10</xref>]. <italic>Bothrops</italic> and <italic>Lachesis</italic> venoms are characterized by three main pathophysiological activities: coagulant, hemorrhagic, and proteolytic or acute inflammatory effects [<xref rid="pntd.0006068.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pntd.0006068.ref014" ref-type="bibr">14</xref>]. Signs and symptoms of vagal stimulation, such as dizziness, blurred vision, diarrhea, abdominal cramps, sinus bradycardia, severe hypotension and shock, may occur after <italic>Lachesis</italic> bites [<xref rid="pntd.0006068.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0006068.ref015" ref-type="bibr">15</xref>]. <italic>Crotalus</italic> venom has neurotoxic, myotoxic and coagulant activities and its systemic manifestations include drowsiness, ptosis, ophthalmoplegia, sagging face muscles, blurred vision, diplopia, myalgia, arthralgia and myoglobinuria, with mild clinical manifestations at the bite site generally [<xref rid="pntd.0006068.ref012" ref-type="bibr">12</xref>].</p><p>Currently, antivenom (AV) immunoglobulins, included in the WHO List of Essential Medicines, are the only treatment available for snakebites envenomings [<xref rid="pntd.0006068.ref016" ref-type="bibr">16</xref>]. In Brazil, the Ministry of Health implemented the National Program for Snakebites Control in 1986 [<xref rid="pntd.0006068.ref017" ref-type="bibr">17</xref>]. Since then, AV production has been carried out by national laboratories and distributed by the Ministry of Health for national use free of charge to patients. Five types of snake liquid AVs are currently available: <italic>Bothrops</italic> AV, <italic>Crotalus</italic> AV, <italic>Bothrops-Crotalus</italic> AV, <italic>Bothrops-Lachesis</italic> AV, and <italic>Micrurus</italic> AV [<xref rid="pntd.0006068.ref004" ref-type="bibr">4</xref>]. In the Amazon and other tropical areas, a major concern regarding snakebites treatment effectiveness relates to the impossibility of wide and timely liquid AV distribution. The lack of an adequate cold chain impairs AV distribution to health facilities available in remote areas and may result in delayed patient care and, ultimately, in higher complications and case fatality rates [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>]. In additon, inadequate storage and transportation may result in loss of material [<xref rid="pntd.0006068.ref004" ref-type="bibr">4</xref>]. To minimize this problem, it has been suggested freeze-drying to improve the stability of AV immunoglobulins. This additional step and addition of different stabilizers lead to AVs with a higher stability compared to liquid formulations, especially in tropical regions where high temperatures could affect the activity of immunoglobulins [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pntd.0006068.ref020" ref-type="bibr">20</xref>]. Physicochemical characterization studies of commercial freeze-dried AVs from India, Mexico, Thailand and Costa Rica showing good quality standards are available in the literature [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0006068.ref020" ref-type="bibr">20</xref>]. However, knowledge about freeze-dried AVs efficacy and safety obtained from clinical trials is still very limited.</p><p>This study was performed to compare the safety and efficacy of a freeze-dried trivalent antivenom with those of the available AV provided by the Brazilian Ministry of Health (MoH), to treat <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> snakebites in the Brazilian Amazon.</p></sec><sec id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Study design and participants</title><p>This was a prospective, randomized, open, phase IIb trial, carried out from June 2005 to May 2008. <italic>Bothrops</italic> snakebites from the <italic>Tropical Medicine Foundation Dr</italic>. <italic>Heitor Vieira Dourado</italic> (FMT-HVD), Manaus, Amazonas state, Brazil were included. <italic>Lachesis</italic> snakebites included were from the local hospitals at Borba (Amazonas state, Brazil), Normandia and Pacaraima (Roraima state, Brazil). <italic>Crotalus</italic> snakebites were included from the local hospitals of Boa Vista and Cant&#x000e1; (Roraima state, Brazil). Eligible patients were male and female subjects aged between 12 and 70 years old. <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> snakebites were diagnosed using clinical, epidemiological and laboratorial evaluations. Exclusion criteria were pregnancy or breastfeeding, previous hematological disorders, known immunodeficiencies (HIV, malignancies, chemotherapy or other immunosuppressive treatments), previous treatment with snake AVs and history of any moderate/severe allergic reactions. Moreover, patients presenting with severe snake envenomings, defined for <italic>Bothrops</italic> and <italic>Lachesis</italic> as life-threatening snakebites with severe bleeding, hypotension, shock and acute renal failure, and for <italic>Crotalus</italic> as intense rhabdomyolisis and severe acute renal failure [<xref rid="pntd.0006068.ref021" ref-type="bibr">21</xref>], were not included.</p></sec><sec id="sec008"><title>Patients&#x02019; selection, interventions and baseline clinical characterization</title><p>After snakebite envenoming diagnosis, patients that fulfilled all inclusion criteria were randomly assigned with allocation ratio 1:1 to one of the following groups:</p><list list-type="order"><list-item><p><bold>Group A</bold>: Freeze-dried trivalent antivenom (FDTAV), produced under GMP conditions by <italic>Butantan Institute</italic> (S&#x000e3;o Paulo, Brazil) in partnership with <italic>Instituto de Biologia do Ex&#x000e9;rcito</italic> (Rio de Janeiro, Brazil). In this study, freeze-drying was performed at the Butantan Institute. Briefly, 20 mL vials were filled with 5 mL of each formulation and loaded on a freeze-dryer Benchmark 1100 (Virtis, USA). The samples were frozen at -40&#x000b0;C and annealed at -10&#x000b0;C for 4 h. The primary drying was conducted at -20&#x000b0;C for 64 h, and the secondary drying at 30&#x000b0;C for 4 h and 200 mTorr.</p></list-item><list-item><p><bold>Group B</bold>: Available <italic>Bothrops</italic>, <italic>Bothrops-Lachesis</italic> and <italic>Bothrops-Crotalus</italic> AVs provided by the MoH (SLAV). In Brazil, snake AV production is standardized and all the AV production from the three national laboratories (<italic>Butantan Institute</italic>, <italic>Ezequiel Dias Foundation</italic> and <italic>Vital Brazil Institute</italic>) is acquired by the MoH for national distribution free of charge.</p></list-item></list><p>A randomization list was computer-generated. When a patient was considered to meet the inclusion criteria and had given her/his informed consent, he/shewas formally recruited and a unique ID number was allocated in the Case Report Form (CRF). After admission, a CRF was filled with the patient's unique ID number, gender, area of occurrence of the snakebite (rural or urban), age (in years), ethnicity, education (in years), anatomical region of the bite, and time from bite to medical assistance (in hours). Clinical examination included the observation of local and systemic manifestations. For <italic>Bothrops</italic> snakebites, laboratorial characterization included clotting time, erythrocyte sedimentation rate, International Normalized Ratio (INR), hemoglobin, leucocyte and platelet counts and plasma levels of fibrinogen, creatinine, urea, lactate dehydrogenase, aspartate transaminase, alanine transaminase and creatine phosphokinase in the plasma. For <italic>Lachesis</italic> and <italic>Crotalus</italic> snakebites, laboratorial characterization included clotting time, INR and plasma levels of fibrinogen, creatinine, urea, and activities of aspartate transaminase, alanine transaminase and creatine phosphokinase in the plasma.</p><p>Twenty minutes after pre-medication with IV hydrocortisone (500 mg), IV cimetidine (300 mg) and oral dexchlorpheniramine (5 mg) (standardized according to local guidelines), AV therapy was given to all patients from both groups in a dosage corresponding to mild or moderate envenomation. For detailed information about the allocation groups and interventions, see <xref ref-type="table" rid="pntd.0006068.t001">Table 1</xref>. Before administration, each FDTAV vial was reconstituted in 20 mL of sterile saline solution (0.9%) with a further dilution in 100 mL before administration. Each SLAV vial was diluted in 100 mL of saline solution 0.9%. Antivenom administration time ranged from 30 to 45 minutes.</p><table-wrap id="pntd.0006068.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.t001</object-id><label>Table 1</label><caption><title>Description of the study allocation groups.</title></caption><alternatives><graphic id="pntd.0006068.t001g" xlink:href="pntd.0006068.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study group</th><th align="left" rowspan="1" colspan="1">Intervention</th><th align="left" rowspan="1" colspan="1">Description of the interventional product</th><th align="left" rowspan="1" colspan="1">Venoms used for production</th><th align="left" rowspan="1" colspan="1">Dosage</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Group A</bold></td><td align="left" rowspan="1" colspan="1">Freeze-dried trivalent antivenom (AV) (FDTAV)</td><td align="left" rowspan="1" colspan="1">Each vial of FDTAV contains heterologous horse F(ab&#x02019;)2, neutralizing at least 100 mg, 60 mg and 30 mg of the reference venoms of <italic>Bothrops jararaca</italic>, <italic>Lachesis muta</italic> and <italic>Crotalus durissus terrificus</italic>, respectively, in mice, sucrose (1 g), NaCl (0.17 g) and phenol (35 mg maximum). Each vial is accompanied by an ampoule containing 20 mL of sterile saline solution (0.9%)</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> genus (<italic>B</italic>. <italic>jararaca</italic> 50.0%, <italic>B</italic>. <italic>alternatus</italic> 12.5%, <italic>B</italic>. <italic>jararacu&#x000e7;u</italic> 12.5%, <italic>B</italic>. <italic>moojeni</italic> 12.5% and <italic>B</italic>. <italic>neuweidi</italic> 12.5%), <italic>Lachesis</italic> genus (<italic>L</italic>. <italic>muta</italic> 100.0%), <italic>Crotalus</italic> genus (<italic>C</italic>. <italic>durissus terrificus</italic> 50.0% and <italic>C</italic>. <italic>d</italic>. <italic>collilineatus</italic> 50.0%)</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> bites: 2 vials to mild cases and 4 vials to moderate cases<break/><italic>Lachesis</italic> bites: 5 vials to non-severe cases<break/><italic>Crotalus</italic> bites: 2,5 vials to mild cases and 5 vials to moderate cases</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Group B</bold>
<xref ref-type="table-fn" rid="t001fn001">[1]</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> bites</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> AV provided by the MoH (SLAV)</td><td align="left" rowspan="1" colspan="1">Each vial contains heterologous horse F(ab&#x02019;)2, neutralizing at least 50 mg of the reference venom of <italic>Bothrops jararaca</italic> in mice, phenol (35 mg maximum) and physiological solution 0.85% q.s. 10 mL</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops jararaca</italic> (50.0%), <italic>B</italic>. <italic>alternatus</italic> (12.5%), <italic>B</italic>. <italic>jararacu&#x000e7;u</italic> (12.5%), <italic>B</italic>. <italic>moojeni</italic> (12.5%) and <italic>B</italic>. <italic>neuweidi</italic> (12.5%)</td><td align="left" rowspan="1" colspan="1">4 vials to mild cases and 8 vials to moderate cases</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Lachesis</italic> bites</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops-Lachesis</italic> AV provided by the MoH (BLMoHA)</td><td align="left" rowspan="1" colspan="1">Each vial contains heterologous horse F(ab&#x02019;)2, neutralizing at least 50 mg and 30 mg of the reference venoms of <italic>Bothrops jararaca</italic> and <italic>Lachesis muta</italic>, respectively, in mice, phenol (35 mg maximum) and physiological solution 0.85% q.s. 10 mL</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> genus (<italic>B</italic>. <italic>jararaca</italic> 50.0%, <italic>B</italic>. <italic>alternatus</italic> 12.5%, <italic>B</italic>. <italic>jararacu&#x000e7;u</italic> 12.5%, <italic>B</italic>. <italic>moojeni</italic> 12.5% and <italic>B</italic>. <italic>neuweidi</italic> 12.5%), <italic>Lachesis</italic> genus (<italic>L</italic>. <italic>muta</italic> 100.0%)</td><td align="left" rowspan="1" colspan="1">10 vials to non-severe cases</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Crotalus</italic> bites</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops-Crotalus</italic> AV provided by the MoH (BCMoHA)</td><td align="left" rowspan="1" colspan="1">Each vial contains heterologous horse F(ab&#x02019;)2, neutralizing at least 50 mg and 15 mg of the reference venoms of <italic>Bothrops jararaca</italic> and <italic>Crotalus durissus terrificus</italic>, respectively, in mice, phenol (35 mg maximum) and physiological solution 0.85% q.s. 10 mL</td><td align="left" rowspan="1" colspan="1"><italic>Bothrops</italic> genus (<italic>B</italic>. <italic>jararaca</italic> 50.0%, <italic>B</italic>. <italic>alternatus</italic> 12.5%, <italic>B</italic>. <italic>jararacu&#x000e7;u</italic> 12.5%, <italic>B</italic>. <italic>moojeni</italic> 12.5% and <italic>B</italic>. <italic>neuweidi</italic> 12.5%), <italic>Crotalus</italic> genus (<italic>C</italic>. <italic>durissus terrificus</italic> 50.0% and <italic>C</italic>. <italic>d</italic>. <italic>collilineatus</italic> 50.0%)</td><td align="left" rowspan="1" colspan="1">5 vials to mild cases and 10 vials to moderate cases</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>[1]</sup> Brazilian Ministry of Health (2001). Manual de diagn&#x000f3;stico e tratamento de acidentes por animais pe&#x000e7;onhentos. Bras&#x000ed;lia: Brazilian Ministry of Health. 120 p.</p></fn></table-wrap-foot></table-wrap><p>Intravenous paracetamol was given on demand for pain. The bitten limb was nursed in the most comfortable position, blisters were aspirated, necrotic tissue was surgically debrided, abscesses were drained, and antibiotic treatment was given accordingly.</p></sec><sec id="sec009"><title>Patients&#x02019; follow-up</title><p>After AV therapy, patients were admitted to the hospital ward for close monitoring during 24 hours. The same laboratorial tests referred above were repeated 4 hours (H4), 12 hours (H12) and 24 hours (H24) after AV therapy. Patients were asked to attend the hospital seven (D7) and fifteen days (D15) after discharge. At follow-up visits, clinical examination was carried out and the above mentioned laboratorial tests were performed in order to investigate clinical evolution of the envenomations and occurrence of late adverse reactions to AV therapy. If the patient did not present for the follow-up visits, the investigator planned a domiciliary visit the following day. Patients who did not present to hospital visits and were not found at domiciliary visits were considered lost to follow-up.</p></sec><sec id="sec010"><title>Safety endpoints</title><p>Primary safety outcome was defined as the presence of signs and symptoms of early adverse reactions of AV therapy represented by urticaria, asthma-like crisis, laryngeal edema and shock, shortly after infusion until the first 24 hours after treatment. Early reactions were treated with intramuscular or subcutaneous adrenaline (1:1000, 0.3&#x02013;0.5 mL), and repeated after 10 minutes if needed. After the symptoms of reaction had subsided, AV therapy was restarted.</p><p>Secondary safety outcome was defined as the presence of late adverse events, namely fever, urticarial, arthralgia, adenomegaly, neurological and renal complications, until D15. After D15, patients were advised to return to the hospital or to contact the study physician by phone in case of any signs of complications. In case of late reactions, treatment consisted of analgesics, anti-histamines and corticotherapy.</p></sec><sec id="sec011"><title>Efficacy endpoints</title><p>For <italic>Bothrops</italic> and <italic>Lachesis</italic> snakebites, primary efficacy outcome was defined as the recovery of hemostasis parameters to normal ranges within the first 24 hours of follow-up. For <italic>Crotalus</italic> snakebites, primary efficacy outcome was defined as the suppression of coagulopathy and improvement of creatine phosphokinase activity within the first 24 hours of follow-up. Secondarily, suppression of neurological manifestations and recovery of other laboratorial parameters to normal ranges within the first 24 hours of follow-up was estimated in both groups. A second dose of four vials of AV was planned to be given if the patient&#x02019;s blood remained totally incoagulable 12 hours after the initial dose, or in case of coagulopathy recurrence, again following the Brazilian Ministry of Health&#x02019;s guidelines [<xref rid="pntd.0006068.ref021" ref-type="bibr">21</xref>]. <italic>Lachesis</italic> and <italic>Crotalus</italic> patients were recruited in remote countryside areas, unfortunately with no availability to some laboratorial analysis used as secondary endpoints.</p></sec><sec id="sec012"><title>Blinding</title><p>This was an open label trial that exclusively relied on laboratorial values for the assessment of the primary efficacy outcome, therefore blinding of laboratory staff was ensured. The laboratory personnel performing the analyses had no direct contact with the investigators and no information regarding the drug administered to the patient.</p></sec><sec id="sec013"><title>Reconstitution test</title><p>Before administration, AV dissolution in 20 mL of sterile saline solution (0.9%) was observed visually as the FDTAV vials were gently agitated by hand for one minute. Successful reconstitution was considered when the dry AV was dissolved into a homogeneous solution.</p></sec><sec id="sec014"><title>Quality control and stability</title><p>Samples of the FDTAV were sent to the <italic>Instituto Nacional de Controle de Qualidade em Sa&#x000fa;de</italic> (INCQS), Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Rio de Janeiro, Brazil, for quality control and stability evaluation. Total protein concentration and proportion of immunoglobulins, nonspecific toxicity, pyrogen levels, microbiological parameters and phenol concentrations were evaluated using standard methods. Anti-<italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> potencies (mg/mL) were estimated by calculating the volume of FDTAV that neutralizes 1 mg of venom in mice. The FDTAV thermal stability was determined by estimating AV potency kept 15 days, one month, three months and one year at 56&#x000b0;C, compared to baseline potency. Methods employed for estimating AV potency [<xref rid="pntd.0006068.ref022" ref-type="bibr">22</xref>] are presented in <xref ref-type="supplementary-material" rid="pntd.0006068.s005">S1 File</xref>. Turbidity and presence of aggregates were observed by visual examination for quality control over time in parallel with potency and before AV administration.</p></sec><sec id="sec015"><title>Statistical methods</title><p>Patients were distributed in two groups according the type of AV received. Baseline epidemiological, laboratorial and clinical characteristics of patients bitten by <italic>Bothrops</italic> were compared by Fisher test or chi-square test, using a 5% significance level. Student's t-test was used for comparison of means. For <italic>Lachesis</italic> and <italic>Crotalus</italic> patients, only a descriptive analysis was conducted because of the small number of cases. The primary efficacy analysis was done on all randomly selected patients finishing the follow-up (per protocol population). The primary efficacy endpoint for <italic>Bothrops</italic> bites, coagulopathy-free efficacy at 48 hours, was analysed using Kaplan-Meier estimates. A two-sided log-rank test was done over the time period using a 5% significance level. All other efficacy endpoints were analyzed with descriptive statistics. Primary safety endpoint frequencies between intervention and control groups were tested by Fisher test or chi-square test, using a 5% significance level, pooling all types of snakebites. Where zeros caused problems with computation of p values, 0.5 was added to all cells [<xref rid="pntd.0006068.ref023" ref-type="bibr">23</xref>,<xref rid="pntd.0006068.ref024" ref-type="bibr">24</xref>]. Statistical analyses were performed using the STATA statistical package version 13 (Stata Corp. 2013).</p></sec><sec id="sec016"><title>Ethics</title><p>Eligible patients were asked to meet the study investigator, who gave detailed explanation of the study protocol according to the patient information sheet. Written consent was requested from the patient or from their parents/guardians for minors. The study protocol was approved by the Research Ethics Committee of the <italic>Instituto de Biologia do Ex&#x000e9;rcito</italic> (IBEx), Rio de Janeiro, Brazil, and by the National Ethical Committee (approval number 001-03/2003).</p></sec></sec><sec sec-type="results" id="sec017"><title>Results</title><sec id="sec018"><title>Patients inclusion</title><p>The assessment and enrollment of ptients in this study is shown in a flow diagram (<xref ref-type="fig" rid="pntd.0006068.g001">Fig 1</xref>). Briefly, out of 244 patients initially screened, 116 were eligible for inclusion: 102 cases of <italic>Bothrops</italic>, 6 cases of <italic>Lachesis</italic> and 8 cases of <italic>Crotalus</italic> snakebites. Of the patients recruited, 65 were assigned to Group A (FDTAV) (58 <italic>Bothrops</italic>, three <italic>Lachesis</italic> and four <italic>Crotalus</italic> bites) and 51 to the Group B (SLAV) (44 <italic>Bothrops</italic>, three <italic>Lachesis</italic> and four <italic>Crotalus</italic> bites). No patient was lost to follow-up.</p><fig id="pntd.0006068.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.g001</object-id><label>Fig 1</label><caption><title>Flow chart of inclusion in the clinical trial.</title></caption><graphic xlink:href="pntd.0006068.g001"/></fig></sec><sec id="sec019"><title>Baseline characterization</title><p><italic>Bothrops</italic> snakebites were more frequent in males (88.2%), and mostly occurred in rural areas (68.6%). The most affected age group was the 16&#x02013;30 years old (43.1%) followed by the 31&#x02013;60 years old (42.2%). Admixed ethnicity was recorded for 95.1% of the included patients. A total of 50.0% of the patients presented 1&#x02013;4 years of education. The most affected anatomical sites were the lower limbs (93.1%). Time elapsed from bite to medical assistance was higher than 6 hours in 34.3% of the cases. <italic>Lachesis</italic> and <italic>Crotalus</italic> bites showed the same general epidemiological characteristics (<xref ref-type="table" rid="pntd.0006068.t002">Table 2</xref>). Baseline laboratorial characteristics were similar in both groups (<xref ref-type="table" rid="pntd.0006068.t003">Table 3</xref> and <xref ref-type="supplementary-material" rid="pntd.0006068.s006">S2 File</xref>). The most frequent manifestations observed at admission in <italic>Bothrops</italic> snakebites were pain (96.1%), edema (96.1%) and local bleeding (30.4%). The most frequent systemic manifestations were nausea (11.8%), acute renal failure (6.9%) and bleeding (6.9%). Vagal manifestations, such as vomiting, bradycardia, hypotension, abdominal pain and blurred vision, were observed in <italic>Lachesis</italic> bites. Myalgia and neurological manifestations, namely palpebral ptosis, diplopia, ophtalmoplegia and dizziness, were recorded for <italic>Crotalus</italic> bite cases (<xref ref-type="table" rid="pntd.0006068.t004">Table 4</xref>). There were no deaths or permanent sequelae in the study.</p><table-wrap id="pntd.0006068.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.t002</object-id><label>Table 2</label><caption><title>Epidemiological characteristics of the patients and comparison between experimental groups.</title></caption><alternatives><graphic id="pntd.0006068.t002g" xlink:href="pntd.0006068.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="4" rowspan="1"><italic>Bothrops</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Lachesis</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Crotalus</italic> bites (number, %)</th></tr><tr><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">p</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">90 (88.2)</td><td align="left" rowspan="1" colspan="1">53 (91.4)</td><td align="left" rowspan="1" colspan="1">37 (84.0)</td><td align="left" rowspan="1" colspan="1">0.258</td><td align="left" rowspan="1" colspan="1">5 (83.3)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">7 (87.5)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">12 (11.8)</td><td align="left" rowspan="1" colspan="1">5 (8.6)</td><td align="left" rowspan="1" colspan="1">7 (16.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (16.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Area of occurrence</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rural</td><td align="left" rowspan="1" colspan="1">70 (68.6)</td><td align="left" rowspan="1" colspan="1">42 (72.4)</td><td align="left" rowspan="1" colspan="1">28 (63.6)</td><td align="left" rowspan="1" colspan="1">0.344</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Urban/Periurban</td><td align="left" rowspan="1" colspan="1">32 (31.4)</td><td align="left" rowspan="1" colspan="1">16 (27.6)</td><td align="left" rowspan="1" colspan="1">16 (36.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age group (in years)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;15</td><td align="left" rowspan="1" colspan="1">12 (11.8)</td><td align="left" rowspan="1" colspan="1">4 (6.9)</td><td align="left" rowspan="1" colspan="1">8 (18.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x02013;30</td><td align="left" rowspan="1" colspan="1">44 (43.1)</td><td align="left" rowspan="1" colspan="1">24 (41.4)</td><td align="left" rowspan="1" colspan="1">20 (45.4)</td><td align="left" rowspan="1" colspan="1">0.193</td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">5 (62.5)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">31&#x02013;60</td><td align="left" rowspan="1" colspan="1">43 (42.2)</td><td align="left" rowspan="1" colspan="1">28 (48.3)</td><td align="left" rowspan="1" colspan="1">15 (34.1)</td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (25.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;61</td><td align="left" rowspan="1" colspan="1">3 (2.9)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="left" rowspan="1" colspan="1">0.292</td><td align="left" rowspan="1" colspan="1">1 (16.7)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ethnicity</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Admixed</td><td align="left" rowspan="1" colspan="1">97 (95.1)</td><td align="left" rowspan="1" colspan="1">53 (91.4)</td><td align="left" rowspan="1" colspan="1">43 (97.7)</td><td align="left" rowspan="1" colspan="1">0.210</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="left" rowspan="1" colspan="1">5 (4.9)</td><td align="left" rowspan="1" colspan="1">5 (8.6)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Education (in years)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Illiterate</td><td align="left" rowspan="1" colspan="1">12 (12.8)</td><td align="left" rowspan="1" colspan="1">7 (13.5)</td><td align="left" rowspan="1" colspan="1">5 (11.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">1&#x02013;4</td><td align="left" rowspan="1" colspan="1">47 (50.0)</td><td align="left" rowspan="1" colspan="1">28 (53.8)</td><td align="left" rowspan="1" colspan="1">19 (45.2)</td><td align="left" rowspan="1" colspan="1">0.938</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">7 (87.5)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">5&#x02013;8</td><td align="left" rowspan="1" colspan="1">13 (13.8)</td><td align="left" rowspan="1" colspan="1">6 (11.5)</td><td align="left" rowspan="1" colspan="1">7 (16.7)</td><td align="left" rowspan="1" colspan="1">0.543</td><td align="left" rowspan="1" colspan="1">4 (66.7)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;8</td><td align="left" rowspan="1" colspan="1">22 (23.4)</td><td align="left" rowspan="1" colspan="1">11 (21.2)</td><td align="left" rowspan="1" colspan="1">11 (26.2)</td><td align="left" rowspan="1" colspan="1">0.642</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Anatomical region of the bite</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Upper limbs</td><td align="left" rowspan="1" colspan="1">7 (6.9)</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">4 (9.1)</td><td align="left" rowspan="1" colspan="1">0.438</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lower limbs</td><td align="left" rowspan="1" colspan="1">95 (93.1)</td><td align="left" rowspan="1" colspan="1">55 (94.8)</td><td align="left" rowspan="1" colspan="1">40 (90.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Time from bite to medical assistance (in hours)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;1</td><td align="left" rowspan="1" colspan="1">8 (11.4)</td><td align="left" rowspan="1" colspan="1">3 (6.8)</td><td align="left" rowspan="1" colspan="1">5 (19.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">1&#x02013;6</td><td align="left" rowspan="1" colspan="1">38 (54.3)</td><td align="left" rowspan="1" colspan="1">23 (52.3)</td><td align="left" rowspan="1" colspan="1">15 (57.7)</td><td align="left" rowspan="1" colspan="1">0.268</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;6</td><td align="left" rowspan="1" colspan="1">24 (34.3)</td><td align="left" rowspan="1" colspan="1">18 (18.2)</td><td align="left" rowspan="1" colspan="1">6 (19.2)</td><td align="left" rowspan="1" colspan="1">0.078</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Group A is the freeze-dried trivalent antivenom (FDTAV); Group B is available <italic>Bothrops</italic>, <italic>Bothrops-Lachesis</italic> and <italic>Bothrops-Crotalus</italic> AVs provided by the MoH (MoHA).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd.0006068.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.t003</object-id><label>Table 3</label><caption><title>Baseline laboratorial features of the included patients and comparison between experimental groups.</title></caption><alternatives><graphic id="pntd.0006068.t003g" xlink:href="pntd.0006068.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="4" rowspan="1"><italic>Bothrops</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Lachesis</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Crotalus</italic> bites (number, %)</th></tr><tr><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">p</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Clotting time</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (0&#x02013;10 min)</td><td align="left" rowspan="1" colspan="1">36 (35.3)</td><td align="left" rowspan="1" colspan="1">17 (29.3)</td><td align="left" rowspan="1" colspan="1">19 (43.2)</td><td align="char" char="." rowspan="1" colspan="1">0.146</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Abnormal (&#x0003e;10 min)</td><td align="left" rowspan="1" colspan="1">66 (64.7)</td><td align="left" rowspan="1" colspan="1">41 (70.7)</td><td align="left" rowspan="1" colspan="1">25 (56.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">5 (62.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Urea</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (15&#x02013;40 mg/dL)</td><td align="left" rowspan="1" colspan="1">56 (54.9)</td><td align="left" rowspan="1" colspan="1">29 (50.0)</td><td align="left" rowspan="1" colspan="1">27 (61.4)</td><td align="char" char="." rowspan="1" colspan="1">0.253</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">5 (62.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;40 mg/dL)</td><td align="left" rowspan="1" colspan="1">46 (45.1)</td><td align="left" rowspan="1" colspan="1">29 (50.0)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Creatinine</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (0.5&#x02013;1.2 mg/dL)</td><td align="left" rowspan="1" colspan="1">95 (93.1)</td><td align="left" rowspan="1" colspan="1">54 (91.4)</td><td align="left" rowspan="1" colspan="1">41 (95.5)</td><td align="char" char="." rowspan="1" colspan="1">0.682</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;1.2 mg/dL)</td><td align="left" rowspan="1" colspan="1">7 (6.9)</td><td align="left" rowspan="1" colspan="1">5 (8.6)</td><td align="left" rowspan="1" colspan="1">2 (4.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>K</bold><sup><bold>+</bold></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (3.6&#x02013;5.2 mmol/L)</td><td align="left" rowspan="1" colspan="1">83 (81.4)</td><td align="left" rowspan="1" colspan="1">48 (82.8)</td><td align="left" rowspan="1" colspan="1">35 (79.6)</td><td align="char" char="." rowspan="1" colspan="1">0.700</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;3.6 mmol/L)</td><td align="left" rowspan="1" colspan="1">19 (18.6)</td><td align="left" rowspan="1" colspan="1">10 (17.2)</td><td align="left" rowspan="1" colspan="1">9 (20.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Na</bold><sup><bold>2+</bold></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (135&#x02013;145 mmol/L)</td><td align="left" rowspan="1" colspan="1">81 (79.4)</td><td align="left" rowspan="1" colspan="1">45 (77.6)</td><td align="left" rowspan="1" colspan="1">36 (81.8)</td><td align="char" char="." rowspan="1" colspan="1">0.609</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;145 mmol/L)</td><td align="left" rowspan="1" colspan="1">21 (20.6)</td><td align="left" rowspan="1" colspan="1">13 (22.4)</td><td align="left" rowspan="1" colspan="1">8 (18.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lactate dehydrogenase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (211&#x02013;423 mg/dL)</td><td align="left" rowspan="1" colspan="1">3 (2.9)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="char" char="." rowspan="1" colspan="1">0.728</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;423 mg/dL)</td><td align="left" rowspan="1" colspan="1">99 (97.1)</td><td align="left" rowspan="1" colspan="1">56 (96.6)</td><td align="left" rowspan="1" colspan="1">43 (97.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Leucocytes</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (4,000&#x02013;10,000 mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">48 (47.0)</td><td align="left" rowspan="1" colspan="1">13 (22.4)</td><td align="left" rowspan="1" colspan="1">35 (79.5)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;10,000 mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">54 (53.0)</td><td align="left" rowspan="1" colspan="1">45 (77.6)</td><td align="left" rowspan="1" colspan="1">9 (20.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hemoglobin</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (female: 12&#x02013;16 g/dL; male: 13&#x02013;18 g/dL)</td><td align="left" rowspan="1" colspan="1">43 (42.2)</td><td align="left" rowspan="1" colspan="1">26 (44.8)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="char" char="." rowspan="1" colspan="1">0.511</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (female: &#x0003c;12 g/dL; male: &#x0003c;13 g/dL)</td><td align="left" rowspan="1" colspan="1">59 (57.8)</td><td align="left" rowspan="1" colspan="1">32 (55.2)</td><td align="left" rowspan="1" colspan="1">27 (61.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Aspartate transaminase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (2&#x02013;38 mg/dL)</td><td align="left" rowspan="1" colspan="1">53 (52.0)</td><td align="left" rowspan="1" colspan="1">25 (43.1)</td><td align="left" rowspan="1" colspan="1">27 (61.4)</td><td align="char" char="." rowspan="1" colspan="1">0.073</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">6 (75.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;38 mg/dL)</td><td align="left" rowspan="1" colspan="1">49 (48.0)</td><td align="left" rowspan="1" colspan="1">33 (56.9)</td><td align="left" rowspan="1" colspan="1">17 (39.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (25.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Alanine transaminase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (2&#x02013;44 mg/dL)</td><td align="left" rowspan="1" colspan="1">56 (54.9)</td><td align="left" rowspan="1" colspan="1">29 (50.0)</td><td align="left" rowspan="1" colspan="1">27 (61.4)</td><td align="char" char="." rowspan="1" colspan="1">0.253</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;44 mg/dL)</td><td align="left" rowspan="1" colspan="1">46 (45.1)</td><td align="left" rowspan="1" colspan="1">29 (50.0)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Creatine phosphokinase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (24&#x02013;190 U/L)</td><td align="left" rowspan="1" colspan="1">49 (48.0)</td><td align="left" rowspan="1" colspan="1">28 (48.3)</td><td align="left" rowspan="1" colspan="1">21 (47.7)</td><td align="char" char="." rowspan="1" colspan="1">0.956</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">5 (62.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;190 U/L)</td><td align="left" rowspan="1" colspan="1">53 (52.0)</td><td align="left" rowspan="1" colspan="1">30 (51.7)</td><td align="left" rowspan="1" colspan="1">23 (52.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fibrinogen</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (150&#x02013;370 mg/dL)</td><td align="left" rowspan="1" colspan="1">25 (24.5)</td><td align="left" rowspan="1" colspan="1">14 (24.1)</td><td align="left" rowspan="1" colspan="1">11 (25.0)</td><td align="char" char="." rowspan="1" colspan="1">0.920</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;150 mg/dL)</td><td align="left" rowspan="1" colspan="1">77 (75.5)</td><td align="left" rowspan="1" colspan="1">44 (75.9)</td><td align="left" rowspan="1" colspan="1">33 (75.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Platelets</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (150.000&#x02013;450.000/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">85 (83.3)</td><td align="left" rowspan="1" colspan="1">49 (84.5)</td><td align="left" rowspan="1" colspan="1">36 (81.8)</td><td align="char" char="." rowspan="1" colspan="1">0.721</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;150.000 mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">17 (16.7)</td><td align="left" rowspan="1" colspan="1">9 (15.5)</td><td align="left" rowspan="1" colspan="1">8 (18.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>International Normalized Ratio</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (1)</td><td align="left" rowspan="1" colspan="1">35 (34.3)</td><td align="left" rowspan="1" colspan="1">22 (37.9)</td><td align="left" rowspan="1" colspan="1">13 (29.5)</td><td align="char" char="." rowspan="1" colspan="1">0.377</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;1)</td><td align="left" rowspan="1" colspan="1">67 (65.7)</td><td align="left" rowspan="1" colspan="1">36 (62.1)</td><td align="left" rowspan="1" colspan="1">31 (70.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Erythrocyte sedimentation rate</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (&#x02264;6 mm in the first hour)</td><td align="left" rowspan="1" colspan="1">2 (2.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (4.5)</td><td align="char" char="." rowspan="1" colspan="1">0.109</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr><tr><td align="left" rowspan="1" colspan="1">Abnormal (&#x0003e;6 mm in the first hour)</td><td align="left" rowspan="1" colspan="1">100 (98.0)</td><td align="left" rowspan="1" colspan="1">58 (100.0)</td><td align="left" rowspan="1" colspan="1">42 (95.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td><td align="left" rowspan="1" colspan="1">&#x02026;/*</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Group A is the freeze-dried trivalent antivenom (FDTAV); Group B is available <italic>Bothrops</italic>, <italic>Bothrops-Lachesis</italic> and <italic>Bothrops-Crotalus</italic> AVs provided by the MoH (SLAV); &#x02026;/*: Test not performed.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd.0006068.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.t004</object-id><label>Table 4</label><caption><title>Baseline clinical features of the included patients and comparison between experimental groups.</title></caption><alternatives><graphic id="pntd.0006068.t004g" xlink:href="pntd.0006068.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="4" rowspan="1"><italic>Bothrops</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Lachesis</italic> bites (number, %)</th><th align="left" colspan="3" rowspan="1"><italic>Crotalus</italic> bites (number, %)</th></tr><tr><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">p</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Local manifestations</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Local pain</td><td align="left" rowspan="1" colspan="1">98 (96.1)</td><td align="left" rowspan="1" colspan="1">56 (96.6)</td><td align="left" rowspan="1" colspan="1">42 (95.5)</td><td align="char" char="." rowspan="1" colspan="1">0.777</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Edema</td><td align="left" rowspan="1" colspan="1">98 (96.1)</td><td align="left" rowspan="1" colspan="1">54 (93.1)</td><td align="left" rowspan="1" colspan="1">44 (100.0)</td><td align="char" char="." rowspan="1" colspan="1">0.076</td><td align="left" rowspan="1" colspan="1">6 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">3 (100.0)</td><td align="left" rowspan="1" colspan="1">8 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Local bleeding</td><td align="left" rowspan="1" colspan="1">31 (30.4)</td><td align="left" rowspan="1" colspan="1">16 (27.6)</td><td align="left" rowspan="1" colspan="1">15 (34.1)</td><td align="char" char="." rowspan="1" colspan="1">0.479</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythema</td><td align="left" rowspan="1" colspan="1">38 (37.3)</td><td align="left" rowspan="1" colspan="1">25 (43.1)</td><td align="left" rowspan="1" colspan="1">13 (29.5)</td><td align="char" char="." rowspan="1" colspan="1">0.161</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Necrosis</td><td align="left" rowspan="1" colspan="1">2 (1.9)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="." rowspan="1" colspan="1">0.213</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary infection</td><td align="left" rowspan="1" colspan="1">37 (36.3)</td><td align="left" rowspan="1" colspan="1">20 (34.5)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="char" char="." rowspan="1" colspan="1">0.665</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blistering</td><td align="left" rowspan="1" colspan="1">3 (2.9)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="char" char="." rowspan="1" colspan="1">0.728</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Paresthesia</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Systemic manifestations</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bleeding</td><td align="left" rowspan="1" colspan="1">7 (6.9)</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">4 (9.1)</td><td align="char" char="." rowspan="1" colspan="1">0.438</td><td align="left" rowspan="1" colspan="1">1 (16.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">2 (2.0)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="char" char="." rowspan="1" colspan="1">0.843</td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Myalgia</td><td align="left" rowspan="1" colspan="1">6 (5.9)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">5 (11.4)</td><td align="char" char="." rowspan="1" colspan="1">0.040</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (25.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="left" rowspan="1" colspan="1">12 (11.8)</td><td align="left" rowspan="1" colspan="1">6 (10.3)</td><td align="left" rowspan="1" colspan="1">6 (13.6)</td><td align="char" char="." rowspan="1" colspan="1">0.609</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute renal failure</td><td align="left" rowspan="1" colspan="1">7 (6.9)</td><td align="left" rowspan="1" colspan="1">5 (8.6)</td><td align="left" rowspan="1" colspan="1">2 (4.5)</td><td align="char" char="." rowspan="1" colspan="1">0.420</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Oliguria</td><td align="left" rowspan="1" colspan="1">4 (3.9)</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td><td align="char" char="." rowspan="1" colspan="1">0.455</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematuria</td><td align="left" rowspan="1" colspan="1">4 (3.9)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1">2 (4.5)</td><td align="char" char="." rowspan="1" colspan="1">0.777</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bradycardia</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypotension</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">4 (66.7)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal pain</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">1 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blurred vision</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (66.7)</td><td align="left" rowspan="1" colspan="1">5 (62.5)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td><td align="left" rowspan="1" colspan="1">4 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Palpebral ptosis</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">4 (50.0)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td><td align="left" rowspan="1" colspan="1">2 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diplopia</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">6 (75.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td><td align="left" rowspan="1" colspan="1">3 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ophtalmoplegia</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (25.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Group A is the freeze-dried trivalent antivenom (FDTAV); Group B is available <italic>Bothrops</italic>, <italic>Bothrops-Lachesis</italic> and <italic>Bothrops-Crotalus</italic> AVs provided by the MoH (SLAV).</p></fn></table-wrap-foot></table-wrap><p>In general, epidemiological, clinical and laboratorial characteristics were similarly distributed in the two study groups within <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> bitten groups.</p></sec><sec id="sec020"><title>Efficacy endpoints analysis</title><p>There were no differences between FDTAV and MoH AV treated groups in the time until patient admission for fibrinogen (p = 0.911) and clotting time (p = 0.982), both reaching normal values over follow-up in patients bitten by <italic>Bothrops</italic> snakes (<xref ref-type="fig" rid="pntd.0006068.g002">Fig 2</xref>). Clotting time, fibrinogen and INR presented normal values 24 hours after AV therapy, for both antivenoms (<xref ref-type="fig" rid="pntd.0006068.g003">Fig 3</xref>). Moreover, creatinine, liver transaminases, creatine phosphokinase and the other laboratorial markers were normal 24 hours after admission in FDTAV and SLAV treated groups.</p><fig id="pntd.0006068.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.g002</object-id><label>Fig 2</label><caption><title>Survival analysis of the primary efficacy endpoint.</title><p>Time until fibrinogen (Part A) and clotting time (Part B) reaching normal values over follow-up of patients bitten by <italic>Bothrops</italic> snakes presented no significant difference between freeze-dried trivalent antivenom (FDTAV) and Ministry of Health standard liquid antivenoms (SLAVs) treated groups.</p></caption><graphic xlink:href="pntd.0006068.g002"/></fig><fig id="pntd.0006068.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.g003</object-id><label>Fig 3</label><caption><title>Primary efficacy endpoint analysis in <italic>Bothrops</italic> snakebites.</title><p>Clotting time, fibrinogen and INR levels 24 hours after AV therapy in freeze-dried trivalent antivenom (FDTAV) and Ministry of Health standard liquid antivenoms (SLAVs) treated groups.</p></caption><graphic xlink:href="pntd.0006068.g003"/></fig><p>For <italic>Lachesis</italic> snakebites, fibrinogen, clotting time and INR presented normal values 24 hours after AV therapy for both antivenoms (<xref ref-type="supplementary-material" rid="pntd.0006068.s007">S3 File</xref>).</p><p>Regarding <italic>Crotalus</italic> snakebites, fibrinogen, clotting time, INR, and creatine phosphokinase presented normal values 24 hours after AV therapy in FDTAV and SLAV treated groups (<xref ref-type="supplementary-material" rid="pntd.0006068.s008">S4 File</xref>). Signs and symptoms such as blurred vision, palpebral ptosis, diplopia and ophtalmoplegia disappeared within the first 24 hours of follow-up. The other laboratorial parameters also returned to normal ranges within the first 24 hours of follow-up for both groups. Renal failure was not seen in this group of patients.</p><p>No patient required a second AV dose after the initial dose because of persistent coagulopathy and no local or coagulopathy recurrence was recorded among the patients. All clinical, both locally and systemically, and laboratorial evaluations remained normal at D7 and D15 in both treatment groups.</p></sec><sec id="sec021"><title>Safety endpoint analysis</title><p>A total of 23 patients presented early adverse events after AV therapy (19.8%). The most common were urticaria (13.8%), pruritus (11.2%), facial flushing (3.4%) and vomiting (3.4%). There was no significant difference in the frequency of early adverse events between patients treated with FDTAV and SLAV (<xref ref-type="table" rid="pntd.0006068.t005">Table 5</xref>). All adverse events were mild and all signs and symptoms of early adverse reactions ceased within 48 hours from management. Late adverse events were not observed at D7 and D15 clinical evaluations. Patients were advised to report these after D15, however no patient returned to the hospital or contacted the study physician by phone complaining about possible late adverse events after that day.</p><table-wrap id="pntd.0006068.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.t005</object-id><label>Table 5</label><caption><title>Adverse events reported in the safety study and comparison between the experimental groups.</title></caption><alternatives><graphic id="pntd.0006068.t005g" xlink:href="pntd.0006068.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Adverse event</th><th align="left" colspan="2" rowspan="1">Total (n = 116)</th><th align="left" colspan="2" rowspan="1">Group A (n = 65)</th><th align="left" colspan="2" rowspan="1">Group B (n = 51)</th><th align="left" rowspan="1" colspan="1">p</th></tr><tr><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any adverse event</td><td align="left" rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">19.8</td><td align="left" rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">16.9</td><td align="left" rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">23.5</td><td align="char" char="." rowspan="1" colspan="1">0.388</td></tr><tr><td align="left" rowspan="1" colspan="1">Urticaria</td><td align="left" rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">13.8</td><td align="left" rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">16.9</td><td align="left" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">9.8</td><td align="char" char="." rowspan="1" colspan="1">0.286</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus</td><td align="left" rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">12.3</td><td align="left" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">9.8</td><td align="char" char="." rowspan="1" colspan="1">0.691</td></tr><tr><td align="left" rowspan="1" colspan="1">Facial flushing</td><td align="left" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">0.811</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.9</td><td align="char" char="." rowspan="1" colspan="1">0.821</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Chills</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasal congestion</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.632</td></tr><tr><td align="left" rowspan="1" colspan="1">Conjunctival hyperemia</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.632</td></tr><tr><td align="left" rowspan="1" colspan="1">Pharyngeal irritation</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.632</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>Group A is the freeze-dried trivalent antivenom (FDTAV); Group B is available <italic>Bothrops</italic>, <italic>Bothrops-Lachesis</italic> and <italic>Bothrops-Crotalus</italic> AVs provided by the MoH (SLAV).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec022"><title>Quality control and stability results</title><p>FDTAV physicochemical analysis showed a total protein concentration of 4.63g%, with 80% of F(ab&#x02019;)<sub>2</sub> immunoglobulins. FDTAV was sterile, atoxic and apyrogenic. Phenol concentration was &#x0003c;3,500 ppm. Antivenom potency for neutralizing <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> activities showed no significant decrease compared to baseline potency over one year of thermostability evaluations at 56&#x000b0;C (<xref ref-type="fig" rid="pntd.0006068.g004">Fig 4</xref>). No visual alterations in turbidity and no aggregates were observed over time and before AV administration.</p><fig id="pntd.0006068.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0006068.g004</object-id><label>Fig 4</label><caption><title>Thermostability evaluations of the freeze-dried trivalent antivenom (FDTAV) at 56&#x000b0;C over one year.</title><p>Antivenom potency for neutralizing <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> activities showed no significant decrease compared to baseline over one year of thermostability evaluations at 56&#x000b0;C.</p></caption><graphic xlink:href="pntd.0006068.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec023"><title>Discussion</title><p>Antivenoms are the only specific treatment for treating most of the snakebite envenomings effects, and play a crucial role in minimizing mortality and morbidity. However, to be part of the primary health care package where snakebites occur, there is an urgent need to ensure availability of safe, effective and affordable AVs, namely in developing countries [<xref rid="pntd.0006068.ref016" ref-type="bibr">16</xref>]. Moreover, innovation in the logistics of AV distribution is also a priority. In Brazil, for instance, current AVs require conservation in adequate facilities (2&#x000b0; to 8&#x000b0;C), which are not always available in remote settings [<xref rid="pntd.0006068.ref004" ref-type="bibr">4</xref>]. Although freeze-dried formulations may become a good alternative for the production of more stable AVs in regions of the world where high temperatures are common and the cold chain is poor, such in the Brazilian Amazon, there is a very limited body of published literature on stability, clinical efficacy and safety for freeze-dried AVs. A main concern is the conservation of the freeze-dried AV pharmacokinetic properties and further neutralizing potency of the antibodies submitted to lyophilization [<xref rid="pntd.0006068.ref025" ref-type="bibr">25</xref>]. Although positive results from thermal characterization of the effect of freeze-drying on equine antibodies and the effectiveness of stabilizers in freeze-dried AVs have been reported [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0006068.ref019" ref-type="bibr">19</xref>], to the best of our knowledge this is the first clinical trial aiming to compare the safety and efficacy of a freeze-dried AV with a liquid formulation. This study did not include data on the possible increase in the cost of AV production due to the freeze-drying process. Future cost studies to address this will be essential.</p><sec id="sec024"><title>Efficacy analysis</title><p>Our results showed that in both groups neutralization of venom-induced bleeding and coagulopathy invariably ceased, and blood coagulability was restored over 24 hours of follow-up of all patients. Since hemostasis disorders have been related to severity and deaths in viperid envenomations, restoration of blood coagulability has been proposed as a relevant target endpoint in snakebite clinical trials [<xref rid="pntd.0006068.ref026" ref-type="bibr">26</xref>,<xref rid="pntd.0006068.ref027" ref-type="bibr">27</xref>]. Actually, systemic manifestations of viperid snakebites are characterized by bleeding, coagulopathy associated with defibrinogenation and incoagulability, with the potential of evolving to hypovolemia and further potentially life-threatening conditions such as hypotension, cardiovascular shock and acute kidney injury in severe cases [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0006068.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pntd.0006068.ref030" ref-type="bibr">30</xref>]. Our results indicate that an improvement in coagulation status might be expected within 6&#x02013;12 hours in most patients and within 24 hours in nearly all patients receiving a single dose of AV [<xref rid="pntd.0006068.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0006068.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pntd.0006068.ref033" ref-type="bibr">33</xref>]. Blood coagulability should be monitored after the initial AV dose and further doses of AV should be administered, if necessary, until coagulability is restored [<xref rid="pntd.0006068.ref031" ref-type="bibr">31</xref>,<xref rid="pntd.0006068.ref033" ref-type="bibr">33</xref>,<xref rid="pntd.0006068.ref034" ref-type="bibr">34</xref>]. Abnormal renal function is also fairly common in viperid envenomings [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0006068.ref035" ref-type="bibr">35</xref>,<xref rid="pntd.0006068.ref036" ref-type="bibr">36</xref>]. Both study groups presented serum creatinine concentrations that restored to normal values within the first 24 hours of follow-up of <italic>Bothrops</italic> snakebites. However, some patients admitted with renal failure may evolve without improvement of kidney injury even after AV administration, as injury was triggered before AV administration [<xref rid="pntd.0006068.ref035" ref-type="bibr">35</xref>,<xref rid="pntd.0006068.ref036" ref-type="bibr">36</xref>]. This needs to be taken in consideration in the interpretation of renal failure as an endpoint in <italic>Bothrops</italic> bites.</p><p><italic>Crotalus</italic> venom may cause systemic myotoxicity, increasing serum levels of creatine kinase [<xref rid="pntd.0006068.ref012" ref-type="bibr">12</xref>]. In addition, the levels of muscle enzymes increase even after properAV therapy [<xref rid="pntd.0006068.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0006068.ref037" ref-type="bibr">37</xref>,<xref rid="pntd.0006068.ref038" ref-type="bibr">38</xref>]. Likewise, even patients who receive proper amounts of antivenom can progress with renal damage because the mechanisms of injury are triggered after snakebite and before the antivenom administration. In this study, however, no patient presented renal failure at admission and normal creatine kinase levels were seen at 24 hours of follow-up of <italic>Crotalus</italic> snakebites. All patients recovered from coagulopathy within 24 hours after therapy with FDTAV or SLAV. Although some neurological manifestations observed in <italic>Crotalus</italic> envenomation do not usually improve rapidly after AV administration [<xref rid="pntd.0006068.ref012" ref-type="bibr">12</xref>], in this trial signs and symptoms such as blurred vision, palpebral ptosis, diplopia and ophtalmoplegia were suppressed within the first 24 hours of follow-up.</p><p>In this study, a second dose of AV was not necessary, since no patient presented the blood totally incoagulable 12 hours after the initial dose or coagulopathy recurrences. Indeed, persistent or recurrent venom antigenemia and even recurrent coagulopathy may be present within 12&#x02013;48 hours in severe envenoming [<xref rid="pntd.0006068.ref039" ref-type="bibr">39</xref>,<xref rid="pntd.0006068.ref040" ref-type="bibr">40</xref>], but severe cases were not included in this trial. Moreover, differences in the efficacy of the available antivenom also explain dissimilar rates of resolution of venom-induced coagulopathy, as observed using AVs from different Latin American countries [<xref rid="pntd.0006068.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="pntd.0006068.ref044" ref-type="bibr">44</xref>]. Furthermore, venom composition is known to vary significantly among snakes of different species further reflecting in AV efficacy [<xref rid="pntd.0006068.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0006068.ref045" ref-type="bibr">45</xref>]. Data concerning <italic>Lachesis and Crotalus</italic> species have limitations in terms of efficacy because of the small number due to the rarity of these cases in the Amazon.</p></sec><sec id="sec025"><title>Safety analysis</title><p>Although the literature suggests that the amount of heterologous proteins is related to the frequency and intensity of adverse reactions [<xref rid="pntd.0006068.ref046" ref-type="bibr">46</xref>], we did not observe a significant increase in the incidence of adverse events in FDTAV compared to SLAV. Although both AVs were manufactured from the same pool of hyperimmune plasma, one concern of this study is the possible formation of insoluble aggregates during the freeze-drying process with further incomplete reconstitution, which has been associated with the development of adverse events during administration [<xref rid="pntd.0006068.ref047" ref-type="bibr">47</xref>]. One hypothesis for the negligible insoluble aggregates formation in the FDTAV is the use of sucrose in the stabilization of the lyophilized AV. The protective effect of polyols like sorbitol and mannitol in the development of turbidity in liquid AVs has already been reported [<xref rid="pntd.0006068.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pntd.0006068.ref050" ref-type="bibr">50</xref>]. More recently, the use of sucrose in the stabilization of liquid or freeze-dried AVs has been described as a better stabilizer than mannitol and sorbitol in the FDTAV formulation [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0006068.ref019" ref-type="bibr">19</xref>].</p><p>Early AV reactions were mild and were promptly reversed by treatment with adrenaline and antihistamines. The incidence of early adverse reactions, all mild and not life-threatening, was similar to two other trials from Brazil and Colombia [<xref rid="pntd.0006068.ref006" ref-type="bibr">6</xref>,<xref rid="pntd.0006068.ref039" ref-type="bibr">39</xref>]. However, generally this frequency was lower than the results from other trials carried out in South America with <italic>Bothrops</italic> bitten patients, which reported incidences ranging from 25 to 87% [<xref rid="pntd.0006068.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pntd.0006068.ref033" ref-type="bibr">33</xref>,<xref rid="pntd.0006068.ref040" ref-type="bibr">40</xref>,<xref rid="pntd.0006068.ref043" ref-type="bibr">43</xref>,<xref rid="pntd.0006068.ref051" ref-type="bibr">51</xref>]. Although antihistamines appear to be of no obvious benefit in preventing acute reactions from antivenoms [<xref rid="pntd.0006068.ref052" ref-type="bibr">52</xref>&#x02013;<xref rid="pntd.0006068.ref054" ref-type="bibr">54</xref>], the pre-sorotherapy regimen used in this study (IV hydrocortisone, IV cimetidine and oral dexchlorpheniramine) may have also contributed to the low incidence of early adverse reactions. Late adverse events were not observed in this trial, in agreement with previous studies showing their absence [<xref rid="pntd.0006068.ref008" ref-type="bibr">8</xref>,<xref rid="pntd.0006068.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pntd.0006068.ref033" ref-type="bibr">33</xref>,<xref rid="pntd.0006068.ref040" ref-type="bibr">40</xref>,<xref rid="pntd.0006068.ref043" ref-type="bibr">43</xref>,<xref rid="pntd.0006068.ref051" ref-type="bibr">51</xref>] or low incidence [<xref rid="pntd.0006068.ref055" ref-type="bibr">55</xref>]. Although no patient returned to the hospital or contacted the study physician complaining about possible late adverse events after D15, patients treated with snake AVsmay present adverse reactions after this day. On-site follow-up completion on this day may represent a limitation of this study that may underestimate the frequency of reactions. A concern for the use of AVs formulated with sucrose has been the possibility of complicating or producing some renal damage [<xref rid="pntd.0006068.ref056" ref-type="bibr">56</xref>], but renal function was normal for all patients after 24 hours of follow-up, indicating that the dosage employed was safe.</p></sec><sec id="sec026"><title>Reconstitution test</title><p>Previous studies reported prolonged reconstitution times of 30 and 90 minutes for some lyophilized AVs [<xref rid="pntd.0006068.ref057" ref-type="bibr">57</xref>,<xref rid="pntd.0006068.ref058" ref-type="bibr">58</xref>], delaying the time of AV administration, wich is a factor related to poor prognosis of snakebites envenomation [<xref rid="pntd.0006068.ref005" ref-type="bibr">5</xref>]. In this study, however, a complete dissolution was observed visually as the FDTAV vials were gently agitated by hand for one minute, in agreement with previous studies where other freeze-dried proteins showed short reconstitution times (lower than 5 minutes) [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0006068.ref059" ref-type="bibr">59</xref>,<xref rid="pntd.0006068.ref060" ref-type="bibr">60</xref>], suggesting maintenance of the stability and neutralizing activity [<xref rid="pntd.0006068.ref060" ref-type="bibr">60</xref>,<xref rid="pntd.0006068.ref061" ref-type="bibr">61</xref>].</p></sec><sec id="sec027"><title>Stability results</title><p>Successful freeze-drying of AVs already used routinely in some continents (despite the lack of published clinical trials) requires the conservation of the physicochemical stability and neutralizing potency of the antibodies over time at room temperature [<xref rid="pntd.0006068.ref018" ref-type="bibr">18</xref>]. In this study, AV potency for neutralizing <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> venom activities showed no significant decrease comparing to baseline over one year of thermostability evaluations at 56&#x000b0;C. Osmolytes such as sucrose or sorbitol are capable of stabilizing antibodies at high temperatures with no significant perturbation in their secondary structure or in their affinity to snake venoms [<xref rid="pntd.0006068.ref048" ref-type="bibr">48</xref>,<xref rid="pntd.0006068.ref049" ref-type="bibr">49</xref>]. Liquid AVs with sorbitol prevent the appearance of turbidity after one year storage at 37&#x000b0;C, but show a partial loss in neutralizing potency in these conditions [<xref rid="pntd.0006068.ref050" ref-type="bibr">50</xref>]. When tested, anti-&#x003b1;-cobratoxin single domain antibodies added with disulfide bonds at 1 mg/mL at a range of elevated temperatures for an hour retainednearly 100% of their initial binding activity [<xref rid="pntd.0006068.ref062" ref-type="bibr">62</xref>].</p></sec><sec id="sec028"><title>Final remarks</title><p>In this study, FDTAV and SLAVs presented the same efficacy based on clinically relevant outcomes in <italic>Bothrops</italic>, <italic>Lachesis</italic> and <italic>Crotalus</italic> bites. Furthermore, there was no significant difference in the incidence of early adverse reactions between patients treated with FDTAV and SLAVs. Only mild early adverse reactions were reported. This freeze-dryed formulation may become a good alternative for the production of more stable AVs in regions of the Amazon where high temperatures are common and the cold chain is poor. Our results indicate such a product should be attainable for a phase III trial.</p></sec></sec><sec sec-type="supplementary-material" id="sec029"><title>Supporting information</title><supplementary-material content-type="local-data" id="pntd.0006068.s001"><label>S1 Checklist</label><caption><title>CONSORT checklist.</title><p>(DOC)</p></caption><media xlink:href="pntd.0006068.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s002"><label>S1 Dataset</label><caption><title>Study database.</title><p>(XLSX)</p></caption><media xlink:href="pntd.0006068.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s003"><label>S1 Appendix</label><caption><title>Ethics approval document.</title><p>(DOCX)</p></caption><media xlink:href="pntd.0006068.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s004"><label>S2 Appendix</label><caption><title>Original study protocol.</title><p>(PDF)</p></caption><media xlink:href="pntd.0006068.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s005"><label>S1 File</label><caption><title>Methods employed for estimating AV potency.</title><p>(DOCX)</p></caption><media xlink:href="pntd.0006068.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s006"><label>S2 File</label><caption><title>Baseline laboratorial features of the included patients and comparison of means between experimental groups in <italic>Bothrops</italic> snakebites.</title><p>(DOCX)</p></caption><media xlink:href="pntd.0006068.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s007"><label>S3 File</label><caption><title>Primary efficacy endpoint analysis in <italic>Lachesis</italic> snakebites.</title><p>For <italic>Lachesis</italic> snakebites, fibrinogen, clotting time and INR presented normal values 24 hours after AV therapy, for freeze-dried trivalent antivenom (FDTAV) and Ministry of Health standard liquid antivenoms (SLAV) treated groups. Creatinine levels were normal since the admission.</p><p>(PPTX)</p></caption><media xlink:href="pntd.0006068.s007.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0006068.s008"><label>S4 File</label><caption><title>Primary efficacy endpoint analysis in <italic>Crotalus</italic> snakebites.</title><p>For <italic>Crotalus</italic> snakebites, fibrinogen, clotting time, INR, and creatine phosphokinase presented normal values 24 hours after AV therapy in FDTAV and Ministry of Health standard liquid antivenoms (SLAV) treated groups.</p><p>(PPTX)</p></caption><media xlink:href="pntd.0006068.s008.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We acknowledge all those individuals from the Army Institute of Biology and Tropical Medicine Foundation Dr. Heitor Vieira Dourado, who provided help during the research. We acknowledge the Butantan Institute staff involved in the freeze-dried trivalent antivenom production, as well as the staff from the hospitals at Borba, Normandia, Pacaraima, Boa Vista and Cant&#x000e1; municipalities for the help during the research.</p></ack><ref-list><title>References</title><ref id="pntd.0006068.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Kasturiratne</surname><given-names>A</given-names></name>, <name><surname>Wickremasinghe</surname><given-names>AR</given-names></name>, <name><surname>Silva</surname><given-names>N</given-names></name>, <name><surname>Gunawardena</surname><given-names>NK</given-names></name>, <name><surname>Pathmeswaran</surname><given-names>A</given-names></name>, <name><surname>Premaratna</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths</article-title>. <source>PLoS Med</source>
<volume>5</volume>: <fpage>1591</fpage>&#x02013;<lpage>1604</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref002"><label>2</label><mixed-citation publication-type="other">WHO. World Health Organization, 2016. Epidemiology [WWW Document]. World Heal. Organ. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/topics/epidemiology/en/">http://www.who.int/topics/epidemiology/en/</ext-link>.</mixed-citation></ref><ref id="pntd.0006068.ref003"><label>3</label><mixed-citation publication-type="other">Brazilian Ministry of Health (2017) Ofidismo: Situa&#x000e7;&#x000e3;o Epidemiol&#x000f3;gica&#x02014;Dados [WWW Document]. Minist. da Sa&#x000fa;de. URL <ext-link ext-link-type="uri" xlink:href="http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/1025-secretaria-svs/vigilancia-de-a-a-z/animais-peconhentos-serpentes/l2-animais-peconhentos-serpentes/13712-situacao-epidemiologica-dados">http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/1025-secretaria-svs/vigilancia-de-a-a-z/animais-peconhentos-serpentes/l2-animais-peconhentos-serpentes/13712-situacao-epidemiologica-dados</ext-link>. (Accessed 1.10.17).</mixed-citation></ref><ref id="pntd.0006068.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>Monteiro</surname><given-names>WM</given-names></name>, <name><surname>Silva</surname><given-names>AMM</given-names></name>, <name><surname>Tambourgi</surname><given-names>DV</given-names></name>, <name><surname>Silva</surname><given-names>IM</given-names></name>, <name><surname>Sampaio</surname><given-names>VS</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Snakebites and Scorpion Stings in the Brazilian Amazon: Identifying Research Priorities for a Largely Neglected Problem</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>9</volume>: <fpage>e0003701</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003701">10.1371/journal.pntd.0003701</ext-link></comment>
<pub-id pub-id-type="pmid">25996940</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Feitosa</surname><given-names>EL</given-names></name>, <name><surname>Sampaio</surname><given-names>VS</given-names></name>, <name><surname>Salinas</surname><given-names>JL</given-names></name>, <name><surname>Queiroz</surname><given-names>AM</given-names></name>, <name><surname>Silva</surname><given-names>IM</given-names></name>, <name><surname>Gomes</surname><given-names>AA</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Older Age and Time to Medical Assistance Are Associated with Severity and Mortality of Snakebites in the Brazilian Amazon: A Case-Control Study</article-title>. <source>PLoS One</source>
<volume>10</volume>: <fpage>e0132237</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0132237">10.1371/journal.pone.0132237</ext-link></comment>
<pub-id pub-id-type="pmid">26168155</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Pardal</surname><given-names>PPO</given-names></name>, <name><surname>Souza</surname><given-names>SM</given-names></name>, <name><surname>Monteiro</surname><given-names>MRCC</given-names></name>, <name><surname>Fan</surname><given-names>HW</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FOS</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Clinical trial of two antivenoms for the treatment of <italic>Bothrops</italic> and <italic>Lachesis</italic> bites in the north eastern Amazon region of Brazil</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>98</volume>: <fpage>28</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="pmid">14702836</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Pierini</surname><given-names>SV</given-names></name>, <name><surname>Warrell</surname><given-names>DA</given-names></name>, <name><surname>Paulo</surname><given-names>A</given-names></name>, <name><surname>Theakston</surname><given-names>RD</given-names></name> (<year>1996</year>) <article-title>High incidence of bites and stings by snakes and other animals among rubber tappers and Amazonian Indians of the Juru&#x000e1; Valley, Acre State, Brazil</article-title>. <source>Toxicon</source>
<volume>34</volume>: <fpage>225</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="pmid">8711756</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name>, <name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>V</given-names></name>, <name><surname>Robles</surname><given-names>A</given-names></name>, <name><surname>Estrada</surname><given-names>R</given-names></name>, <name><surname>Segura</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>A randomized double-blind clinical trial of two antivenoms in patients bitten by <italic>Bothrops atrox</italic> in Colombia</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>90</volume>: <fpage>696</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="pmid">9015522</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Souza</surname><given-names>ARB</given-names></name> (<year>2002</year>) <article-title>Snakebite by <italic>Bothrops atrox</italic> (Lin. 1758) in the State of Amazonas&#x02014;Brazil: Study of 212 cases with identified snake</article-title>. <source>Rev Patol Trop</source>
<volume>31</volume>: <fpage>259</fpage>&#x02013;<lpage>268</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Torres</surname><given-names>J</given-names></name>, <name><surname>Torres</surname><given-names>M</given-names></name>, <name><surname>Arroyo-Parejo</surname><given-names>M</given-names></name> (<year>1995</year>) <article-title>Coagulation disorders in bushmaster envenomation</article-title>. <source>Lancet</source>
<volume>346</volume>: <fpage>449</fpage>&#x02013;<lpage>450</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Assakura</surname><given-names>MT</given-names></name>, <name><surname>Furtado</surname><given-names>MF</given-names></name>, <name><surname>Mandelbaum</surname><given-names>FR</given-names></name> (<year>1992</year>) <article-title>Biochemical and biological differentiation of the venoms of the lancehead vipers (<italic>Bothrops atrox</italic>, <italic>Bothrops asper</italic>, <italic>Bothrops marajoensis</italic> and <italic>Bothrops moojeni</italic>)</article-title>. <source>Comp. Biochem. Physiol. Part B Comp. Biochem</source>
<volume>102</volume>: <fpage>727</fpage>&#x02013;<lpage>732</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref012"><label>12</label><mixed-citation publication-type="book"><name><surname>Azevedo-Marques</surname><given-names>M</given-names></name>, <name><surname>Hering</surname><given-names>S</given-names></name>, <name><surname>Cupo</surname><given-names>P</given-names></name> (<year>2009</year>) <chapter-title>Acidente Crot&#x000e1;lico</chapter-title> In: <collab>Sarvier</collab> (Ed.), <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Haddad-Jr</surname><given-names>V</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FS</given-names></name>, <name><surname>M&#x000e1;laque</surname><given-names>CMS</given-names></name>, <name><surname>Wen</surname><given-names>FH</given-names></name>. <source>Animais Pe&#x000e7;onhentos no Brasil</source>. <publisher-name>Sarvier</publisher-name>, <publisher-loc>S&#x000e3;o Paulo</publisher-loc>, pp. <fpage>108</fpage>&#x02013;<lpage>115</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Freitas-De-Sousa</surname><given-names>LA</given-names></name>, <name><surname>Amazonas</surname><given-names>DR</given-names></name>, <name><surname>Sousa</surname><given-names>LF</given-names></name>, <name><surname>Sant&#x02019;Anna</surname><given-names>SS</given-names></name>, <name><surname>Nishiyama</surname><given-names>MY</given-names></name>, <name><surname>Serrano</surname><given-names>SMT</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Comparison of venoms from wild and long-term captive <italic>Bothrops atrox</italic> snakes and characterization of batroxrhagin, the predominant class PIII metalloproteinase from the venom of this species</article-title>. <source>Biochimie</source>
<volume>118</volume>: <fpage>60</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.biochi.2015.08.006">10.1016/j.biochi.2015.08.006</ext-link></comment>
<pub-id pub-id-type="pmid">26276061</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Sousa</surname><given-names>LF</given-names></name>, <name><surname>Nicolau</surname><given-names>CA</given-names></name>, <name><surname>Peixoto</surname><given-names>PS</given-names></name>, <name><surname>Bernardoni</surname><given-names>JL</given-names></name>, <name><surname>Oliveira</surname><given-names>SS</given-names></name>, <name><surname>Portes-Junior</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Comparison of Phylogeny, Venom Composition and Neutralization by Antivenom in Diverse Species of <italic>Bothrops</italic> Complex</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>7</volume>: <fpage>e2442</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002442">10.1371/journal.pntd.0002442</ext-link></comment>
<pub-id pub-id-type="pmid">24069493</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Souza</surname><given-names>RCG</given-names></name>, <name><surname>Nogueira</surname><given-names>APB</given-names></name>, <name><surname>Lima</surname><given-names>T</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name> (<year>2007</year>) <article-title>The Enigma of the North Margin of the Amazon River: Proven <italic>Lachesis</italic> Bites in Brazil, Report of Two Cases, General Considerations about the Genus and Bibliographic Review</article-title>. <source>Bull Chicago Herpetol Soc</source>
<volume>42</volume>: <fpage>105</fpage>&#x02013;<lpage>115</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref016"><label>16</label><mixed-citation publication-type="book"><collab>WHO</collab> (<year>2010</year>) <source>Guidelines for the Production Control and Regulation ol Snake Antivenom Immunoglobulins</source>. <publisher-name>WHO</publisher-name>, <publisher-loc>Geneva</publisher-loc>.</mixed-citation></ref><ref id="pntd.0006068.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Feitosa</surname><given-names>ES</given-names></name>, <name><surname>Sampaio</surname><given-names>V</given-names></name>, <name><surname>Sachett</surname><given-names>J</given-names></name>, <name><surname>Castro</surname><given-names>DB</given-names></name>, <name><surname>Noronha</surname><given-names>MDN</given-names></name>, <name><surname>Lozano</surname><given-names>JLL</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Snakebites as a largely neglected problem in the Brazilian Amazon: highlights of the epidemiological trends in the States of Amazonas</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>48</volume>: <fpage>34</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-0105-2013">10.1590/0037-8682-0105-2013</ext-link></comment>
<pub-id pub-id-type="pmid">26061369</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Herrera</surname><given-names>M</given-names></name>, <name><surname>Tattini-Junior</surname><given-names>V</given-names></name>, <name><surname>Pitombo</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>J</given-names></name>, <name><surname>Borgognoni</surname><given-names>C</given-names></name>, <name><surname>Baudrit</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Freeze-dried snake antivenoms formulated with sorbitol, sucrose or mannitol: comparison of their stability in an accelerated test</article-title>. <source>Toxicon</source>
<volume>90</volume>: <fpage>56</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2014.07.015">10.1016/j.toxicon.2014.07.015</ext-link></comment>
<pub-id pub-id-type="pmid">25091348</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Herrera</surname><given-names>M</given-names></name>, <name><surname>Solano</surname><given-names>D</given-names></name>, <name><surname>G&#x000f3;mez</surname><given-names>A</given-names></name>, <name><surname>Villalta</surname><given-names>M</given-names></name>, <name><surname>Vargas</surname><given-names>M</given-names></name>, <name><surname>S&#x000e1;nchez</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2017</year>). <article-title>Physicochemical characterization of commercial freeze-dried snake antivenoms</article-title>. <source>Toxicon</source>
<volume>126</volume>: <fpage>32</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2016.12.004">10.1016/j.toxicon.2016.12.004</ext-link></comment>
<pub-id pub-id-type="pmid">27956243</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rojas</surname><given-names>G</given-names></name>, <name><surname>Espinoza</surname><given-names>M</given-names></name>, <name><surname>Lomonte</surname><given-names>B</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name> (<year>1990</year>) <article-title>Effect of storage temperature on the stability of the liquid polyvalent antivenom produced in Costa Rica</article-title>. <source>Toxicon</source>
<volume>28</volume>: <fpage>101</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="pmid">2330601</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref021"><label>21</label><mixed-citation publication-type="book"><collab>Brazilian Ministry of Health</collab> (<year>2016</year>) <source>Guia de Vigil&#x000e2;ncia em Sa&#x000fa;de</source>, <edition>1st ed</edition>, <publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de. Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de. Departamento de Vigil&#x000e2;ncia das Doen&#x000e7;as Transmiss&#x000ed;veis</publisher-name>
<publisher-loc>Brasilia</publisher-loc>.</mixed-citation></ref><ref id="pntd.0006068.ref022"><label>22</label><mixed-citation publication-type="book"><collab>Brazilian Ministry of Health</collab> (<year>2000</year>) <source>Farmacopeia Brasileira</source>, <edition>4th ed</edition>
<publisher-name>Anvisa</publisher-name>, <publisher-loc>Bras&#x000ed;lia</publisher-loc>.</mixed-citation></ref><ref id="pntd.0006068.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Deeks</surname><given-names>J</given-names></name>, <name><surname>Higgings</surname><given-names>J</given-names></name> (<year>2010</year>) <source>Statistical algorithms in Review Manager</source>
<volume>5</volume>.</mixed-citation></ref><ref id="pntd.0006068.ref024"><label>24</label><mixed-citation publication-type="book"><name><surname>Pagano</surname><given-names>M</given-names></name>, <name><surname>Gauvreau</surname><given-names>K</given-names></name> (<year>2000</year>) <source>Principles of Biostatistics</source>, <edition>2nd ed</edition>
<publisher-name>Brooks/Cole</publisher-name>, <publisher-loc>Belmont</publisher-loc>.</mixed-citation></ref><ref id="pntd.0006068.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Sarciaux</surname><given-names>J-M</given-names></name>, <name><surname>Mansour</surname><given-names>S</given-names></name>, <name><surname>Hageman</surname><given-names>MJ</given-names></name>, <name><surname>Nail</surname><given-names>SL</given-names></name> (<year>1999</year>) <article-title>Effects of Buffer Composition and Processing Conditions on Aggregation of Bovine IgG during Freeze-Drying</article-title>. <source>J Pharm Sci</source>
<volume>88</volume>: <fpage>1354</fpage>&#x02013;<lpage>1361</lpage>. <pub-id pub-id-type="pmid">10585234</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Ho</surname><given-names>M</given-names></name>, <name><surname>Warrell</surname><given-names>MJ</given-names></name>, <name><surname>Warrell</surname><given-names>DA</given-names></name>, <name><surname>Bidwell</surname><given-names>D</given-names></name>, <name><surname>Voller</surname><given-names>A</given-names></name> (<year>1986</year>) <article-title>A critical reappraisal of the use of enzyme-linked immunosorbent assays in the study of snake bite</article-title>. <source>Toxicon</source>
<volume>24</volume>: <fpage>211</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="pmid">3520955</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Sano-Martins</surname><given-names>IS</given-names></name>, <name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>Castro</surname><given-names>SCB</given-names></name>, <name><surname>Tomy</surname><given-names>SC</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FOS</given-names></name>, <name><surname>Jorge</surname><given-names>MT</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration in patients envenomed by <italic>Bothrops</italic> snakes</article-title>. <source>Toxicon</source>
<volume>32</volume>: <fpage>1045</fpage>&#x02013;<lpage>1050</lpage>. <pub-id pub-id-type="pmid">7801340</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref028"><label>28</label><mixed-citation publication-type="book"><name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FOS</given-names></name>, <name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>M&#x000e1;laque</surname><given-names>CMS</given-names></name>, <name><surname>Haddad-Jr</surname><given-names>V</given-names></name> (<year>2003</year>) <source>Venomous animals in Brazil: biology, clinic and therapeutics of envenomations</source>. <publisher-loc>S&#x000e3;o Paulo</publisher-loc>, <publisher-name>Sarvier; FAPESP</publisher-name>
<fpage>468</fpage> p.</mixed-citation></ref><ref id="pntd.0006068.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Otero-Pati&#x000f1;o</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Epidemiological, clinical and therapeutic aspects of Bothrops asper bites</article-title>. <source>Toxicon</source>
<volume>54</volume>: <fpage>998</fpage>&#x02013;<lpage>1011</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2009.07.001">10.1016/j.toxicon.2009.07.001</ext-link></comment>
<pub-id pub-id-type="pmid">19591857</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref030"><label>30</label><mixed-citation publication-type="book"><name><surname>Warrell</surname><given-names>DA</given-names></name> (<year>2004</year>) <chapter-title>Epidemiology, Clinical Features and Management of Snake Bites in Central and South America</chapter-title>, in: <collab>Cornell University Press</collab> (Ed.), <name><surname>Campbell</surname><given-names>J.</given-names></name>, <name><surname>Lamar</surname><given-names>W. W</given-names></name>. (Eds.), <source>Venomous Reptiles of the Western Hemisphere</source>. <publisher-name>Cornell University Press</publisher-name>, <publisher-loc>Ithaca</publisher-loc>, pp. <fpage>709</fpage>&#x02013;<lpage>761</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FOS</given-names></name>, <name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Leite</surname><given-names>RP</given-names></name>, <name><surname>Nishioka</surname><given-names>SA</given-names></name>, <etal>et al</etal> (<year>1993</year>) <article-title>Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (<italic>Bothrops jararaca</italic>) in S&#x000e3;o Paulo, Brazil</article-title>. <source>Q J Med</source>
<volume>85</volume>: <fpage>315</fpage>&#x02013;<lpage>325</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Otero-Pati&#x000f1;o</surname><given-names>R</given-names></name>, <name><surname>Segura</surname><given-names>&#x000c1;</given-names></name>, <name><surname>Herrera</surname><given-names>M</given-names></name>, <name><surname>Angulo</surname><given-names>Y</given-names></name>, <name><surname>Le&#x000f3;n</surname><given-names>G</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab&#x02019;)2] antivenoms, in <italic>Bothrops asper</italic> bites in Colombia</article-title>. <source>Toxicon</source>
<volume>59</volume>: <fpage>344</fpage>&#x02013;<lpage>355</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2011.11.017">10.1016/j.toxicon.2011.11.017</ext-link></comment>
<pub-id pub-id-type="pmid">22146491</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Otero-Pati&#x000f1;o</surname><given-names>R</given-names></name>, <name><surname>Cardoso</surname><given-names>J</given-names></name>, <name><surname>Higashi</surname><given-names>H</given-names></name>, <name><surname>Nunez</surname><given-names>V</given-names></name>, <name><surname>Diaz</surname><given-names>A</given-names></name>, <name><surname>Toro</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for <italic>Bothrops</italic> snake bites in Uraba, Colombia. The Regional Group on Antivenom Therapy Research (REGATHER)</article-title>. <source>Am J Trop Med Hyg</source>
<volume>58</volume>: <fpage>183</fpage>&#x02013;<lpage>189</lpage>. <pub-id pub-id-type="pmid">9580075</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Castro</surname><given-names>SCB</given-names></name>, <name><surname>Ribeiro</surname><given-names>L</given-names></name>, <name><surname>Franca</surname><given-names>FOS</given-names></name>, <name><surname>Sbrogio de Almeida</surname><given-names>ME</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>A randomized &#x0201c;blinded&#x0201d; comparison of two doses of antivenom in the treatment of <italic>Bothrops</italic> envenoming in Sao Paulo, Brazil</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>89</volume>: <fpage>111</fpage>&#x02013;<lpage>114</lpage>. <pub-id pub-id-type="pmid">7747293</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Amaral</surname><given-names>CFS</given-names></name>, <name><surname>Rezende</surname><given-names>NA</given-names></name>, <name><surname>Silva</surname><given-names>OA</given-names></name>, <name><surname>Ribeiro</surname><given-names>MMF</given-names></name>, <name><surname>Magalh&#x000e3;es</surname><given-names>RA</given-names></name>, <name><surname>Reis</surname><given-names>RJ</given-names></name>, <etal>et al</etal> (<year>1986</year>) <article-title>Insufici&#x000ea;ncia renal aguda secund&#x000e1;ria a acidentes of&#x000ed;dicos botr&#x000f3;pico e crot&#x000e1;lico. An&#x000e1;lise de 63 casos</article-title>. <source>Rev Inst Med Trop Sao Paulo</source>
<volume>28</volume>: <fpage>220</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">3563305</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>J</given-names></name>, <name><surname>Beatriz Mesa</surname><given-names>M</given-names></name>, <name><surname>Duque</surname><given-names>E</given-names></name>, <name><surname>Rodr&#x000ed;guez</surname><given-names>O</given-names></name>, <name><surname>Luis Arango</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Complications of <italic>Bothrops</italic>, <italic>Porthidium</italic>, and <italic>Bothriechis</italic> snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital</article-title>. <source>Toxicon</source>
<volume>40</volume>: <fpage>1107</fpage>&#x02013;<lpage>1114</lpage>. <pub-id pub-id-type="pmid">12165312</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Azevedo-Marques</surname><given-names>MM</given-names></name>, <name><surname>Hering</surname><given-names>SE</given-names></name>, <name><surname>Cupo</surname><given-names>P</given-names></name> (<year>1987</year>) <article-title>Evidence that <italic>Crotalus durissus terrificus</italic> (South American rattlesnake) envenomation in human causes myolysis rather than hemolysis</article-title>. <source>Toxicon</source>
<volume>11</volume>: <fpage>1163</fpage>&#x02013;<lpage>1168</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Cupo</surname><given-names>P</given-names></name>, <name><surname>Azevedo-Marques</surname><given-names>MM</given-names></name>, <name><surname>Hering</surname><given-names>SE</given-names></name> (<year>1990</year>) <article-title>Acute myocardial infarction-like enzyme profile in human victims of <italic>Crotalus durissus terrificus</italic> envenoming</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>84</volume>: <fpage>447</fpage>&#x02013;<lpage>451</lpage>. <pub-id pub-id-type="pmid">2260185</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Le&#x000f3;n</surname><given-names>G</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>J</given-names></name>, <name><surname>Rojas</surname><given-names>G</given-names></name>, <name><surname>Toro</surname><given-names>MJB</given-names></name>, <name><surname>Rodr&#x000ed;guez</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of <italic>Bothrops asper</italic> bites in Colombia</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>100</volume>: <fpage>1173</fpage>&#x02013;<lpage>1182</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.trstmh.2006.01.006">10.1016/j.trstmh.2006.01.006</ext-link></comment>
<pub-id pub-id-type="pmid">16698053</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>J</given-names></name>, <name><surname>Rojas</surname><given-names>G</given-names></name>, <name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>V</given-names></name>, <name><surname>D&#x000ed;az</surname><given-names>A</given-names></name>, <name><surname>Miranda</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in <italic>Bothrops</italic> and <italic>Porthidium</italic> snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms</article-title>. <source>Toxicon</source>
<volume>37</volume>: <fpage>895</fpage>&#x02013;<lpage>908</lpage>. <pub-id pub-id-type="pmid">10340829</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Laing</surname><given-names>GD</given-names></name>, <name><surname>Yarleque</surname><given-names>A</given-names></name>, <name><surname>Marcelo</surname><given-names>A</given-names></name>, <name><surname>Rodriguez</surname><given-names>E</given-names></name>, <name><surname>Warrell</surname><given-names>DA</given-names></name>, <name><surname>Theakston</surname><given-names>RDG</given-names></name> (<year>2004</year>) <article-title>Preclinical testing of three south American antivenoms against the venoms of five medically-important Peruvian snake venoms</article-title>. <source>Toxicon</source>
<volume>44</volume>: <fpage>103</fpage>&#x02013;<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2004.03.020">10.1016/j.toxicon.2004.03.020</ext-link></comment>
<pub-id pub-id-type="pmid">15225568</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Rojas</surname><given-names>E</given-names></name>, <name><surname>Quesada</surname><given-names>L</given-names></name>, <name><surname>Arce</surname><given-names>V</given-names></name>, <name><surname>Lomonte</surname><given-names>B</given-names></name>, <name><surname>Rojas</surname><given-names>G</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name> (<year>2005</year>) <article-title>Neutralization of four Peruvian Bothrops sp. snake venoms by polyvalent antivenoms produced in Per&#x000fa; and Costa Rica: Preclinical assessment</article-title>. <source>Acta Trop</source>
<volume>93</volume>: <fpage>85</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.actatropica.2004.09.008">10.1016/j.actatropica.2004.09.008</ext-link></comment>
<pub-id pub-id-type="pmid">15589801</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Smalligan</surname><given-names>R</given-names></name>, <name><surname>Cole</surname><given-names>J</given-names></name>, <name><surname>Brito</surname><given-names>N</given-names></name>, <name><surname>Laing</surname><given-names>GD</given-names></name>, <name><surname>Mertz</surname><given-names>BL</given-names></name>, <name><surname>Manock</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms</article-title>. <source>BMJ</source>
<volume>329</volume>: <fpage>1129</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.329.7475.1129">10.1136/bmj.329.7475.1129</ext-link></comment>
<pub-id pub-id-type="pmid">15539665</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Theakston</surname><given-names>R</given-names></name>, <name><surname>Laing</surname><given-names>G</given-names></name>, <name><surname>Fielding</surname><given-names>C</given-names></name>, <name><surname>Lascano</surname><given-names>A</given-names></name>, <name><surname>Touzet</surname><given-names>J-M</given-names></name>, <name><surname>Vallejo</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Treatment of snake bites by <italic>Bothrops</italic> species and <italic>Lachesis muta</italic> in Ecuador: laboratory screening of candidate antivenoms</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>89</volume>: <fpage>550</fpage>&#x02013;<lpage>554</lpage>. <pub-id pub-id-type="pmid">8560538</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Furtado</surname><given-names>MFD</given-names></name>, <name><surname>Maruyama</surname><given-names>M</given-names></name>, <name><surname>Kamiguti</surname><given-names>AS</given-names></name>, <name><surname>Antonio</surname><given-names>LC</given-names></name> (<year>1991</year>) <article-title>Comparative study of nine <italic>Bothrops</italic> snake venoms from adult female snakes and their offspring</article-title>. <source>Toxicon</source>
<volume>29</volume>: <fpage>219</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="pmid">1646500</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Wingert</surname><given-names>WA</given-names></name>, <name><surname>Chan</surname><given-names>L</given-names></name> (<year>1988</year>) <article-title>Rattlesnake bites in southern California and rationale for recommended treatment</article-title>. <source>West J Med</source>
<volume>148</volume>: <fpage>37</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="pmid">3277335</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Cromwell</surname><given-names>MEM</given-names></name>, <name><surname>Hilario</surname><given-names>E</given-names></name>, <name><surname>Jacobson</surname><given-names>F</given-names></name> (<year>2006</year>) <article-title>Protein aggregation and bioprocessing</article-title>. <source>AAPS J</source>
<volume>8</volume>: <fpage>E572</fpage>&#x02013;<lpage>E579</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1208/aapsj080366">10.1208/aapsj080366</ext-link></comment>
<pub-id pub-id-type="pmid">17025275</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Rodrigues-Silva</surname><given-names>R</given-names></name>, <name><surname>Antunes</surname><given-names>GFC</given-names></name>, <name><surname>Velarde</surname><given-names>DT</given-names></name>, <name><surname>Santoro</surname><given-names>MM</given-names></name> (<year>1999</year>) <article-title>Thermal stability studies of hyperimmune horse antivenoms</article-title>. <source>Toxicon</source>
<volume>37</volume>: <fpage>33</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="pmid">9920478</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Rodrigues-Silva</surname><given-names>R</given-names></name>, <name><surname>Martins</surname><given-names>MS</given-names></name>, <name><surname>Magalh&#x000e3;es</surname><given-names>A</given-names></name>, <name><surname>Santoro</surname><given-names>MM</given-names></name> (<year>1997</year>) <article-title>Purification and stability studies of immunoglobulins from <italic>Lachesis muta muta</italic> antivenom</article-title>. <source>Toxicon</source>
<volume>35</volume>: <fpage>1229</fpage>&#x02013;<lpage>1238</lpage>. <pub-id pub-id-type="pmid">9278972</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Segura</surname><given-names>A</given-names></name>, <name><surname>Herrera</surname><given-names>M</given-names></name>, <name><surname>Gonz&#x000e1;lez</surname><given-names>E</given-names></name>, <name><surname>Vargas</surname><given-names>M</given-names></name>, <name><surname>Solano</surname><given-names>G</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Stability of equine IgG antivenoms obtained by caprylic acid precipitation: Towards a liquid formulation stable at tropical room temperature</article-title>. <source>Toxicon</source>
<volume>53</volume>: <fpage>609</fpage>&#x02013;<lpage>615</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2009.01.012">10.1016/j.toxicon.2009.01.012</ext-link></comment>
<pub-id pub-id-type="pmid">19673074</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>Marcopito</surname><given-names>L</given-names></name>, <name><surname>Cardoso</surname><given-names>J</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>F</given-names></name>, <name><surname>Malaque</surname><given-names>C</given-names></name>, <name><surname>Ferrari</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites</article-title>. <source>BMJ</source>
<volume>318</volume>: <fpage>1451</fpage>&#x02013;<lpage>1453</lpage>. <pub-id pub-id-type="pmid">10346769</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Bucaretchi</surname><given-names>F</given-names></name>, <name><surname>Douglas</surname><given-names>JL</given-names></name>, <name><surname>Fonseca</surname><given-names>MRCC</given-names></name>, <name><surname>Zambrone</surname><given-names>FAD</given-names></name>, <name><surname>Vieira</surname><given-names>RJ</given-names></name> (<year>1994</year>) <article-title>Snake bites in children: antivenom early reaction frequency in patients pretreated with histamine antagonists H1 and H2 and hydrocortisone</article-title>. <source>Rev Inst Med Trop S&#x000e3;o Paulo</source>
<volume>36</volume>: <fpage>451</fpage>&#x02013;<lpage>457</lpage>. <pub-id pub-id-type="pmid">7569613</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Habib</surname><given-names>AG</given-names></name> (<year>2011</year>) <article-title>Effect of pre-medication on early adverse reactions following antivenom use in snakebite: A systematic review and meta-analysis</article-title>. <source>Drug Saf</source>
<volume>34</volume>: <fpage>869</fpage>&#x02013;<lpage>880</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/11592050-000000000-00000">10.2165/11592050-000000000-00000</ext-link></comment>
<pub-id pub-id-type="pmid">21879781</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>L</given-names></name>, <name><surname>Tyburn</surname><given-names>B</given-names></name>, <name><surname>Bucher</surname><given-names>B</given-names></name>, <name><surname>Pecout</surname><given-names>F</given-names></name>, <name><surname>Ketterle</surname><given-names>J</given-names></name>, <name><surname>Rieux</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Prevention of thromboses in human patients with <italic>Bothrops lanceolatus</italic> envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Research Group on Snake Bites in Martinique</article-title>. <source>Am J Trop Med Hyg</source>
<volume>52</volume>: <fpage>419</fpage>&#x02013;<lpage>426</lpage>. <pub-id pub-id-type="pmid">7771608</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Itkin</surname><given-names>YM</given-names></name>, <name><surname>Trujillo</surname><given-names>TC</given-names></name> (<year>2005</year>) <article-title>Intravenous immunoglobulin-associated acute renal failure: case series and literature review</article-title>. <source>Pharmacother</source>
<volume>25</volume>: <fpage>886</fpage>&#x02013;<lpage>892</lpage>.</mixed-citation></ref><ref id="pntd.0006068.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Hill</surname><given-names>RE</given-names></name>, <name><surname>Bogdan</surname><given-names>GM</given-names></name>, <name><surname>Dart</surname><given-names>RC</given-names></name> (<year>2001</year>) <article-title>Time to reconstitution: Purified Fab antivenom vs. unpurified IgG antivenom</article-title>. <source>Toxicon</source>
<volume>39</volume>: <fpage>729</fpage>&#x02013;<lpage>731</lpage>. <pub-id pub-id-type="pmid">11072054</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Quan</surname><given-names>AN</given-names></name>, <name><surname>Quan</surname><given-names>D</given-names></name>, <name><surname>Curry</surname><given-names>SC</given-names></name> (<year>2010</year>) <article-title>Improving Crotalidae polyvalent immune Fab reconstitution times</article-title>. <source>Am J Emerg Med</source>
<volume>28</volume>: <fpage>593</fpage>&#x02013;<lpage>595</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajem.2009.02.008">10.1016/j.ajem.2009.02.008</ext-link></comment>
<pub-id pub-id-type="pmid">20579555</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Schersch</surname><given-names>K</given-names></name>, <name><surname>Betz</surname><given-names>O</given-names></name>, <name><surname>Garidel</surname><given-names>P</given-names></name>, <name><surname>Muehlau</surname><given-names>S</given-names></name>, <name><surname>Bassarab</surname><given-names>S</given-names></name>, <name><surname>Winter</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Systematic Investigation of the Effect of Lyophilizate Collapse on Pharmaceutically Relevant Proteins I: Stability after Freeze-Drying</article-title>. <source>J Pharm Sci</source>
<volume>99</volume>: <fpage>2256</fpage>&#x02013;<lpage>2278</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jps.22000">10.1002/jps.22000</ext-link></comment>
<pub-id pub-id-type="pmid">20039389</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Searles</surname><given-names>JA</given-names></name>, <name><surname>Carpenter</surname><given-names>JF</given-names></name>, <name><surname>Randolph</surname><given-names>TW</given-names></name> (<year>2001</year>). <article-title>Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine T(g)' pharmaceutical lyophilization</article-title>. <source>J Pharm Sci</source>
<volume>90</volume>: <fpage>872</fpage>&#x02013;<lpage>887</lpage>. <pub-id pub-id-type="pmid">11458336</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Gerring</surname><given-names>D</given-names></name>, <name><surname>King</surname><given-names>TR</given-names></name>, <name><surname>Branton</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>Validating a faster method for reconstitution of Crotalidae Polyvalent Immune Fab (ovine)</article-title>. <source>Toxicon</source>
<volume>69</volume>: <fpage>42</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2012.12.005">10.1016/j.toxicon.2012.12.005</ext-link></comment>
<pub-id pub-id-type="pmid">23305624</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Theakston</surname><given-names>RDG</given-names></name>, <name><surname>Warrell</surname><given-names>DA</given-names></name>, <name><surname>Griffiths</surname><given-names>E</given-names></name> (<year>2003</year>) <article-title>Report of a WHO workshop on the standardization and control of antivenoms</article-title>. <source>Toxicon</source>
<volume>41</volume>: <fpage>541</fpage>&#x02013;<lpage>557</lpage>. <pub-id pub-id-type="pmid">12676433</pub-id></mixed-citation></ref><ref id="pntd.0006068.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>GP</given-names></name>, <name><surname>Liu</surname><given-names>JH</given-names></name>, <name><surname>Zabetakis</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>JL</given-names></name>, <name><surname>Goldman</surname><given-names>ER</given-names></name> (<year>2017</year>) <article-title>Thermal stabilization of anti-&#x003b1;-cobratoxin single domain antibodies</article-title>. <source>Toxicon</source>
<volume>129</volume>: <fpage>68</fpage>&#x02013;<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2017.02.008">10.1016/j.toxicon.2017.02.008</ext-link></comment>
<pub-id pub-id-type="pmid">28209480</pub-id></mixed-citation></ref></ref-list></back></article>